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OBJECTIVES: 
This study was done to known the spectrum of cardiac manifestations in patients with scrub 
typhus infection and to determine the incidence of myocarditis in these patients. This study 
identifies the factors contributing to myocarditis, and to compare the outcomes in patients with 
and without myocarditis and to know the mechanism of myocarditis. 
METHODS: 
This prospective cohort study was conducted in a teaching institute in south India; all patients 
with acute febrile illness and a clinical syndrome suggestive of scrub typhus infection and 
fulfilling the diagnostic criteria were recruited and followed up till their hospital stay. A 
diagnosis of myocarditis was considered in patients with myocardial injury (troponin level 
measured more than 14 pg/ml) with coexisting myocardial dysfunction (left ventricular ejection 
fraction less than 50%). Descriptive statistics were obtained for all variables in the study. 
Categorical and continuous variables were compared for outcome by using the fisher’s exact test 
and student t test respectively. All continuous data were expressed as mean ± SD unless the data 
was not normally distributed. A p value of < 0.05 was considered statistically significant for all 
analysis. The presence of myocarditis, myocardial injury and dysfunction were correlated with 
mortality. This was expressed as odds ratio (OR) with 95% confidence interval (CI). A 
multivariate logistic regression analysis was performed to assess and identify those factors which 
were independently associated with myocarditis. 
RESULTS AND CONCLUSIONS: 
This prospective cohort study was conducted over a period of 20 months (June 2012 to January 
2014). The study cohort comprised of 81 patients with a mean ± SD age of 49.41 ± 16.07 and 
presenting at 8.11 ± 3.11 days of illness. There was a slight female predominance observed, with 
female: male ratio of 1.3:1. In this cohort of scrub typhus patients the cardiac manifestations 
varied from asymptomatic patients with non specific ECG findings to myocarditis and 
cardiogenic shock. The incidence of myocarditis was 21%. Myocardial injury was seen in 61.7% 
and myocardial dysfunction was observed in 30.9% participants. A mild grade of diastolic 
dysfunction was observed in 18% of the study participants. Pericardial involvement was seen in 
51% in the form of mild to moderate pericardial effusion. ECG changes were non specific; sinus 
tachycardia was the predominant ECG finding in this cohort. The development of myocarditis 
increased the need for ventilation, prolonged the duration of ICU and hospital stay. There was no 
biochemical, hematological or physiological factors predicting myocarditis and myocarditis was 
not associated with worse mortality in our cohort. 
1. INTRODUCTION 
 
Scrub typhus, a rickettsial infection caused by Orientia Tsutsugamushi is endemic to a 
part of the world known as the "tsutsugamushi triangle" which extends from Japan to Australia, 
and to Pakistan and Afghanistan. Since the 19
th
 century, scrub typhus is reported more and more 
frequently. It accounts for nearly fifty percent of the cases of acute undifferentiated febrile illness 
in our hospital(1). It causes significant morbidity and mortality; in a cohort of 116 critically ill 
patients, the mortality rate was 24% (2). Clinical features may vary from acute febrile illness 
without localizing symptoms or signs to multi-organ involvement leading to death. It is known 
that scrub typhus can cause myocardial dysfunction but the magnitude of involvement and the 
impact of myocardial dysfunction and injury on various outcomes are unknown. In other disease 
processes such as severe H1N1 infection, myocarditis occurs frequently and is associated with 
increased mortality (3). As symptoms are non-specific, the diagnosis may be delayed or missed.  
The contribution of myocardial disease to severity of illness and death in patients with scrub 
typhus is not established. As not all scrub typhus patients develop myocardial involvement, 
knowing what predispose them may help in early recognition. Scrub typhus causes vasculitis due 
to disseminated endothelial infection of the small vessels and by secondary immune mediated 
mononuclear inflammatory reaction. Myocarditis occurs due to disseminated endothelial 
infection of the small vessels or by secondary immune mediated mononuclear inflammation(4). 
The frequency and extent of cardiac involvement in scrub typhus is not known. 
 
2. AIM 
 
To characterize the cardiac manifestations in patients presenting with scrub typhus infection, 
hospitalized in tertiary care centre in South India. 
 
 
 
 
 
 
 
 
 
 
 
 
3. OBJECTIVES 
 
1. To study the spectrum of cardiac manifestations in scrub typhus infection. 
 
2. To evaluate the incidence of myocarditis 
 
3. To compare the outcome of scrub typhus patients with and without myocarditis. 
 
4. To study the factors contributing to the development of myocarditis in Scrub Typhus. 
 
5. To study the mechanism of myocarditis. 
 
 
 
 
 
 
 
4. REVIEW OF LITERATURE 
 
4.1 NATURAL HISTORY 
Scrub typhus is a mite borne zoonotic rickettsial infection, the causative organism 
being Orientia tsutsugamushi. It is seen in the terrain areas of the ‗tsutsugamushi‘ triangle which 
is a geographical region comprising South east Asia and Southwest Pacific (5). Scrub typhus was 
known as early as the 3
rd
 century in China; however the magnitude of the disease was evident in 
the 2
nd
 world war as many soldiers were victims of the chigger mite. Tsutsugamushi is a term 
with Japanese origin for tsutsuga which meant ―illness‖ and mushi: insect or creature″.  
 
Figure 1 –‘Tsutsugamushi’ TRIANGLE 
 
 
Scrub typhus is endemic to China, Japan, India, Pakistan, Korea, Thailand, Taiwan and 
Malaysia, and in the north tropical regions of Australia. Taiwan is the centre of the 
tsutsugamushi triangle; however the reported incidence is highest in Korea (6). The annul new 
case detection is about 1 million (7).  
The first reported cases in India were in 1934, in Himachal Pradesh (8). Scrub typhus has been 
increasingly reported as a significant cause of febrile illness in many parts of India (5,9,10). A 
study done in CMC Vellore in 2007 showed 47.5% of the cases of acute undifferentiated febrile 
illness in south India were due to scrub typhus (1). 
4.2 LIFE CYCLE 
The disease is caused in humans following the introduction of Orientia tsutsugamushi. It 
is propagated by the bite of a larval-stage of trombiculid mite (chigger) (4, 5). Occupation 
associated with significant exposure to bushes and grasses, which are the breeding ground of the 
mites is found to be a common way by which the individuals acquire this disease (6). These 
mites have a four-stage life cycle namely egg, larva, nymph, and adult which is summarised in 
Figure 2 (6). The feeding behaviour of the larva is peculiar in that, it feeds only one time. After 
the blood meal, it detaches itself from the host and subsequently matures. The mature form is the 
nymph which later becomes an adult. They are free living parasites in the soil. Humans are 
accidental hosts with small rodents and mammals being the definitive hosts. 
 
 Figure 2 – LIFECYCLE OF SCRUB TYPHUS 
 
There have been no reports of contact transmission of infection between individuals (6). The 
impact of temperature and humidity on the parasite influences the epidemics (6). Transmission 
occurs year-round in tropical areas and in the subcontinent during the rainy season(7). 
 
4.3 MICROBIOLOGY 
O. tsutsugamushi is a gram-negative coccobacillus. It is different from the typhus group 
rickettsiae both in terms of genetic composition as well as cell wall composition 
(O.tsutsugamushi does not have a slime layer on its outer membrane). It requires a cell enriched 
media for propagation.  
O. tsutsugamushi is unique in its method of dissemination. Following infection of the 
host cells, it incorporates the host cell membranes and emerges as budding forms from the 
infected cells. It then undergoes phagocytosis by the neighboring host cells. Phospholipase A2 
(rickettsial) mediates the entry into host cells, which further leads to release of phagosomes 
causing injury to host (11). They undergo rapid and widespread dissemination following the 
initial inoculation into the skin. The presence of O. tsutsugamushi was identified on staining 
mononuclear cells in the peripheral blood in three out of seven patients studied with acute scrub 
typhus (12). 
Three major variants or strains of O. tsutsugamushi have been identified. They are Karp, Kato 
and Gilliam. Infection with one strain does not prevent reinfection with a different strain. 
    
 
 
 
 
 
 
4.4 PATHOGENESIS      
The pathogen multiples at the site of inoculation following the bite, and subsequently 
induces local and systemic manifestations of infection. The severity of illness depends on both 
host and pathogen related factors. Pathogen related factors may be attributed to the fact that 
different strains (Karp, Gilliam and Kato) of O. Tsutsugamushi may contribute differently to 
disease severity.            
The bacterium multiplies and disseminates within the human host and its principal target 
being the endothelial cells. They have been located in endothelial cells of heart, lung, brain, liver, 
kidney, pancreas, skin and also isolated from macrophages of liver and spleen in post mortem 
samples (13). Initially it was thought that the organism gains entry to the target organs through 
the lymphatic system. However in 2001, Walsh et al (12) demonstrated the pathogen within 
mononuclear white blood cells in patients with acute infection, suggesting the possibility of a 
direct blood borne spread.  
The immune response induced by O. tsutsugamushi is a combination of humoral and cell 
mediated immunity. The rise of cytokines during an acute infection was demonstrated as far back 
as 1997 by Iwasaki et al (14). In a small series of patients, they have shown a significant rise in 
macrophage colony stimulating factor (M-CSF), interferon gamma (IFN-γ) and granulocyte 
colony stimulating factor (G-CSF).  
Only a few patients showed a rise in tumour necrosis factor (TNF-α) during the infection 
but it continued to rise during convalescence in those who had severe disease. These 
observations demonstrated that the macrophage and T lymphocyte response may be the driving 
factor in immunity against infection. 
 More recently, Fost et al (15) have demonstrated indirect evidence for cytotoxic 
lymphocyte (cytotoxic T cell and natural killer cell) activation during acute infection that may 
play a key role in destroying the infected host cells. The parasite has evolved to evade the 
immune mechanisms of the host. In view of the high mortality rate of untreated disease, these 
mechanisms are of clinicopathological significance.  
Cho et al (16) showed that live O. tsutsugamushi down regulates the expression of the 
glycoprotein 96 (gp96) in infected macrophages and endothelial cells compared to non- infected 
cells in cell culture. This molecule  is expressed in the endoplasmic reticulum of cells and plays a 
central role in major histocompatibility complex class I (MHC I) mediated antigen presentation, 
functioning of dendritic cells, antibody production and cross priming of immune cells (16). 
Suppression of this glycoprotein may be one mechanism by which the pathogen neutralizes the 
host immune response. 
4.5 RISK FACTORS  
Scrub typhus is characteristically a geographically focal disease, transmission is seen in 
the south East Asian and Pacific regions that consist of focal locations of scrub vegetations.  The 
mites live on these vegetations and the moisture and temperature conditions are ideal for 
propagation of chiggers and their small rodent hosts. When humans enter these mite islands the 
risk of disease transmission from chigger bites may be extremely high. Farmers account for 
approximately fifty percent of all reported cases (6). Scrub typhus infection is strongly associated 
with people working in fields (17). Scrub typhus is seen more commonly in people aged 40 to 60 
years of age, but young children have higher rates of infection than young adults (18). Even 
though scrub typhus infection is seen throughout the year the incidence is highest during June to 
October (19). 
4.6 CLINICAL MANIFESTATIONS 
Scrub typhus causes a spectrum of illness from asymptomatic mild and self-limiting to 
fatal illness with multiorgan dysfunction. The incubation period following successful inoculation 
ranges from an average of 6 to 21 days. Initial symptoms of the disease include fever, myalgia, 
headache, cough and gastrointestinal symptoms (20). The severity of the symptoms depends on 
the host susceptibility and the virulence of the bacteria or both (20). The classic case description 
includes an eschar at the site of chigger feeding, regional lymphadenopathy and a maculopapular 
rash (1,20). 
Cutaneous manifestations appear five to eight days after the onset of fever. A macular or 
maculopapular rash occurs on the trunk which could progress centripetally to involve the limb. 
Presence of an eschar at the wound site is the diagnostic clue of significance (7). An eschar is 
seen at sites where the skin surfaces are in contact or the clothes bind, such as the neck, axilla, 
waist, groin and inguinal area. It is seen less frequently on South Asians in view of the dark skin 
and is easily found on Caucasian and East Asian patients. It starts as a papule, progresses to 
develop central necrosis followed by development of a blackened crust surrounded by an 
erythematous halo simulating a cigarette burn (7). Eschar can be detected in 46-86% of scrub 
typhus patients (21). Kundavaram et al (22) found significant differences in the distribution of 
eschar among males and females. In females eschar was predominantly seen in the chest and 
abdomen (42.3%) whereas in males it was seen mostly in the axilla, groin and genitalia (55.8%). 
The most likely places to find an eschar were the groin and abdomen. Most common systemic 
findings include generalized lymphadenopathy and splenomegaly (1,20). 
In patients with a history of exposure in a geographic area, endemic to scrub typhus 
presenting with fever, rash, eschar, generalized or regional lymphadenopathy, scrub typhus 
should be considered in the differential diagnosis. Other differentials to be considered include 
rickettsial pox, dengue, Mediterranean spotted fever, leptospirosis and murine typhus.     
4.7 COMPLICATIONS  
Systemic complications of scrub typhus which are commonly reported include interstitial 
pneumonia, meningoencephalitis, acute renal failure and gastrointestinal bleeding. Multiple 
organ dysfunction is also a common entity. Varghese et al (23) have reported similar 
complications in a cohort of 623 patients from south India; multi-organ dysfunction was seen in 
one third of the patients and the case fatality rate was 9%.  
Patients with shock requiring vasoactive agents, central nervous system dysfunction and 
renal failure were independent predictors of mortality. The incidence of various organ 
dysfunctions in a cohort of 116 critically ill patients with scrub typhus revealed that respiratory 
organ dysfunction predominated and was present in 96.6% (2). Cardiovascular dysfunction was 
present in 61.7% and renal and hepatic dysfunction in 63.8% or patients. Ninety one (85.2%) 
patients had dysfunction of three or more organ systems and mechanical ventilation was required 
in 102 (87.9%) patients. The mortality in this cohort of patients was 24%, duration of fever and 
APACHE II score independently predicted mortality (2). In a case control study comparing 
severe scrub typhus with those with mild disease, Kim et al (10) observed that age, absence of 
eschar, leucopenia and hypoalbuminemia to be associated with severe complications. It is 
evident that patients with scrub typhus infection typically present with significant physiological 
derangement of multiple organ systems. Despite the high prevalence of multi-organ dysfunction 
and the severity of illness, scrub typhus patients had fewer than predicted mortality. 
4.8 DIAGNOSIS 
As with all rickettsial diseases, no laboratory test is diagnostically reliable in the early 
phases of scrub typhus. The disease is usually recognized when clinicians correlate the presence 
of compatible clinical signs, symptoms and laboratory features, with epidemiologic clues (e.g., 
recent exposure to environments in which chiggers are known or suspected to be present). Most 
patients with severe illness develop thrombocytopenia, transaminitis, hyperbilirubinemia, and 
deranged creatinine. Leucopenia as well as leukocytosis can occur, but most have a normal white 
blood cell count. 
Serologic assays (IFA, indirect immunoperoxidase and enzyme immunoassays) are the 
mainstays of laboratory diagnosis, and PCR amplification of Orientia genes from eschar and 
blood is also effective. 
4.9 TREATMENT 
 
Chloramphenicol was the first drug reported to be effective in management of scrub 
typhus, and is the first line agent in many endemic areas. Intravenous doses or oral doses of 250 
to 500 mg every sixth hourly is effective. Doxycycline (100 mg orally or intravenously twice 
daily) is now the standard of care. Azithromycin can be used as an alternative agent in special 
circumstances. Doxycycline resistant scrub typhus is emerging especially in parts of Thailand, 
hence need for azithromycin or high antibiotic regimen is warranted. 
4.10 CARDIOVASCULAR COMPLICATIONS IN SCRUB TYPHUS 
 
The incidence of myocarditis associated with scrub typhus is unknown. Myocardial 
involvement in scrub typhus was first described by Levine‘s post-mortem findings in a series of 
31 scrub typhus patients during World War II. He described varying degrees of myocardial 
inflammation in 25 (81%) cases (24). However the contribution of myocardial disease to the 
cause of death in these individuals was not established as scrub typhus causes multiorgan 
dysfunction. Orientia tsutsugamushi an intracellular parasite causes destruction of endothelial 
cells and perivascular infiltration of leukocytes resulting in focal and disseminated vasculitis and 
perivasculitis involving the small blood vessels (25). Myocarditis may occur during acute 
rickettsial infection due to disseminated endothelial infection of the small vessels or by 
secondary immune mediated mononuclear inflammatory reaction. This could account for  the 
myocardial inflammation with resultant left ventricular dysfunction causing significant mortality 
due to cardiac involvement in the disease (25). 
In scrub typhus myocarditis, nonspecific damage to myocytes, with minimal necrosis, can 
occur as a result of vascular endothelial damage and an inflammatory response consisting of 
infiltrating lymphocytes, monocytes, plasma cells associated with haemorrhage and oedema 
induced by adjacent infection. Lack of coronary artery involvement has been demonstrated by 
histopathology and coronary angiography (24,25). Similarly, native heart valves are spared. 
Focal petechial haemorrhages observed in many organs have been noted in the subendocardium 
and subepicardium (24,26). The lack of significant myofibril necrosis may explain the absence of 
chronic cardiac sequelae (26). Proliferation of Rickettsia tsutsugamushi was observed in the 
vascular endothelial cells of the myocardium, indicates that endomyocardial biopsy may be a 
useful diagnostic test to prove myocardial involvement in R. tsutsugamushi (25). 
4.10.1 CLINICAL FEATURES IN MYOCARDITIS 
The clinical findings of myocarditis are nonspecific and indistinguishable from other 
aetiologies and may include fever, shortness of breath, and orthopnea (25,26). Clinical 
manifestations form a large spectrum which might occur as ECG abnormalities which are not 
symptomatic to fatal cardiogenic shock. Individuals with fulminant myocarditis present with 
severe hemodynamic compromise requiring vasopressors and / or mechanical circulatory support 
(27). 
Physical examination may reveal elevated jugular venous pulsations, rales, a ventricular gallop, 
or systolic murmur in the apex (25,26). 
4.10.2 ELECTROCARDIOGRAPHIC FINDINGS IN SCRUB 
MYOCARDITIS 
 
Electrocardiogram (ECG) abnormalities in scrub typhus have been studied. 
Cardiovascular complications of scrub typhus were more frequent in the pre antibiotic era. Fang 
et al (28) compared ECG findings in 98 cases of scrub typhus infection with 101 asymptomatic 
normal individuals. Occurrence of flat T waves in the precordial leads to tall and peaked T waves 
in leads V2-4 was noted in both acute and convalescent stages. Occurrences of sinus arrhythmia 
with some beats below 60 per minute in the convalescent stages were more frequent. ECG 
abnormalities were commonly seen with acute illness. 
In the acute phase of the infection bradycardia predominates and in the convalescent 
stage, sinus arrhythmia, prominent u waves and T wave abnormality predominates (29). The use 
of appropriate antibiotics has reduced the complications of scrub typhus in the antibiotic era. In a 
recent study from Korea, Kim et al (30) showed the presence of an ECG abnormality in more 
than 30% of scrub typhus patients. Scrub typhus patients with an arrhythmic ECG at presentation 
had associated elevated blood urea nitrogen (BUN) and creatinine levels. When these patients 
were followed up, the patients with persistent abnormal ECG were associated with high BUN, 
creatinine levels, and had an increased rate of ICU admission with prolonged stay. The presence 
of ECG abnormalities in scrub typhus patients are non specific and do not reflect cardiac 
involvement. It necessitates further evaluation in the form of cardiac enzymes and 
echocardiography study.  
4.10.3 CARDIAC BIOMARKERS IN MYOCARDITIS 
Serum cardiac biomarkers such as troponin (I and T) and creatinine kinase (CK) are 
routinely assessed in patients with clinical suspicion of myocarditis, but are limited by a low 
predictive value. In a study by Lauer et al (31), out of 80 patient with suspected myocarditis only 
28 (35%) had elevated troponin. The sensitivity of Troponin T levels at a cutoff >0.1 ng/mL was 
found to be 53% and a specificity of 94% to predict lymphocytic myocarditis. A positive 
predictive value of 93%, and a negative predictive value of 56% was identified in lymphocytic 
myocarditis (31)(32). Smith and coworkers (32) in the Multicenter Myocarditis trial examined 
the value of troponin I in autoimmune myocarditis. The sensitivity of an elevated troponin I for 
the cohort was low (34%), however it was found to have a high specificity (89%). The sensitivity 
improved with a shorter duration of symptoms (<4 weeks) (32) and it also had an acceptable 
positive predictive value at 82%. Hence it is recommended to measure either troponin T or I 
whenever a diagnosis of myocarditis is suspected. 
4.10.4 IMAGING IN MYOCARDITIS 
Non invasive modalities of imaging techniques of diagnostic importance include 
echocardiography, imaging (gallium or indium- labeled antimyosin antibodies) and magnetic 
resonance imaging (MRI). They aid in the diagnosis of myocarditis. 
The recommended standard of care for initial evaluation of patients with suspected 
myocarditis is Echocardiography. Pinamonti et al (33) in their retrospective study, analyzed the 
echocardiography findings among 42 patients, who had proven biopsy confirmed  myocarditis 
due to various etiologies. Left ventricular dysfunction was a common finding (69%). Left 
ventricular enlargement was minimal or absent, hence suggesting other conditions causing acute 
dilated cardiomyopathy. Right ventricular dysfunction occurred in 23% of the cohort. Patients 
who presented with history of chest pain or features of heart block had preserved normal 
ventricular size and function. Regional wall motion abnormalities were seen in 64% of the 
cohort. Left ventricular hypertrophy was seen in 15% of patients and it showed complete 
resolution over several months. Thus, echocardiography findings can be varied but relatively 
nonspecific. However echocardiogram is the key noninvasive method of detecting impaired 
ventricular function in suspected myocarditis, even when subclinical (33,34). 
4.10.5 ECHOCARDIOGRAPHY: TO ASSESS CARDIAC FUNCTION 
The following parameters of cardiac functions are assessed by a non invasive imaging technique 
- Echocardiography. 
Cardiac Output (CO) and Stroke Volume (SV) 
Cardiac output is calculated by echocardiography through any structure, which will be 
sufficient enough to measure cross sectional area and also to gauge the velocity of blood flow. 
This could be through any of the valves, the pulmonary artery or the aorta.  
The left ventricular outflow method is the easiest place to measure cardiac output and has 
the least variability.(35). The left ventricular outflow tract (LVOT) diameter changes very little 
through the systole and the diastole. It is assumed to be a constant variable and it closely 
approximates a circle. The LVOT diameter is measured during systole in the parasternal long 
axis view, next to the attachment point of the leaflets. The cross sectional area (CSA) is 
calculated by the machine. 
The velocity of the blood flow against the time duration of systole is measured by the 
LVOT velocity time integral (VTI), in the units of cm. It is measured by angulating the 
transducer towards the chest wall, in the apical five chamber view. The PWD cursor is guided on 
the LVOT and is kept as close as possible to the aortic valve, excluding the sample volume. 
Application of digital software online helps to trace out the VTI by ultrasound machine. 
The following are required for cardiac output calculation: 
1) LVOT diameter 
2) Heart rate 
3) LVOT VTI 
Cardiac output = Heart Rate x Stroke Volume 
Stroke Volume= LVOT area x LVOT VTI 
= π (LVOT diameter/2) ^2 x LVOT VTI. 
 
  
 
 
 
 
 
 
 
Cardiac index (CI) 
This parameter derives a relationship between the cardiac output (left ventricle per minute) to the 
body surface area. It hence correlates cardiac performance to the individual‘s body size. It is 
measured in terms of liters per minute per meter square. (L/min/m
2
). 
Cardiac index (CI) = cardiac output (CO) / basal surface area (BSA) 
The cardiac index at rest is 2.6–4.2 L/min/m2. 
The cardiac index is often used in medical as well as cardiac intensive care medicine. It is a 
useful indicator of the cardiac functioning as a pump .It correlates directly, the total blood 
volume pumped by the heart with the body surface area of the individual. 
Cardiogenic shock is a presence of hypotension with a combination of low cardiac index (less 
than 1.8 L/min/m
2).
 
Stroke volume index 
Stroke volume (SV) is the blood volume pumped from a ventricle with each heart beat. 
This is calculated by deducting the blood volume at the end of heart beat (end systolic volume) 
from the blood volume prior to the heart beat (end diastolic volume).This is done by measuring 
the volumes of ventricles from an echocardiogram. This term stroke volume can be applied to 
either of the two ventricles of the heart; however it commonly refers to the left ventricle. Each 
ventricular stroke volumes are generally equal and in a healthy 70 kg man measures 
approximately 70 mL. 
The product of heart rate with blood volume is called stroke volume, which determines the 
cardiac output. Stroke volume can also be used to calculate ejection fraction, which is stroke 
volume divided by end-diastolic volume. Certain conditions and disease states decrease stroke 
volume. However; the parameter stroke volume correlates well with cardiac function. 
Men have higher stroke volumes on an average than women. This is due to the larger size of the 
heart. Stroke volume is dependent on factors such as contractility, heart size, duration of 
contraction, after load and preload (end-diastolic volume).  
The method of correlating stroke volume to body size of an individual is called Stroke volume 
index (SVI). This is calculated by the formula: 
SVI = SV / BSA 
SYSTEMIC VASCULAR RESISTANCE INDEX 
The resistance offered to the free flow of blood, which must be overcome to successfully 
push the blood through the circulation is called as vascular resistance. The resistance of the 
peripheral circulation is called systemic vascular resistance (SVR) and is also called as total 
peripheral resistance. The resistance offered by the pulmonary vasculature is known as the 
pulmonary vascular resistance (PVR). A decrease in the diameter of the blood vessel is called 
vasoconstriction, which in turn increases SVR, whereas vasodilatation is an increase in diameter, 
which causes a decrease in SVR. 
This is measured by using the Units such as dyn·s·cm
−5
, Pascal seconds per cubic metre 
(Pa·s/m³) or it can also be derived by cardiac output (measured in l/min) and pressure (measured 
in mmHg) given as mmHg·min/l. This is used by pediatric cardiologists, and is referred to as 
hybrid reference units (HRU), also called as Wood units. By multiplying 8 Wood units can be 
converted to MPa·s/m
3
 or to dyn·s·cm
−5
 by multiplying by 80. 
SVR is defined by using the analogy of ohms law. This is measured by the ratio of drop in mean 
pressure to the cumulative flow in the systemic circulation. The basis of calculating resistance is 
that flow is equal to driving pressure and is divided by the resistance. The systemic vascular 
resistance can hence be calculated in units of dyn·s·cm
−5
 as 
 Systemic vascular resistance index (SVRI) is a method to correlate the systemic vascular 
resistance to the size of the individual. This following formula can be applied to calculate: 
SVRI= SVR / BSA 
A low SVRI is seen in vasoplegic shock. A high SVRI indicates a cardiogenic or hypovolemic 
shock. This is a useful tool in assessment of the type of shock. 
Assessment of left ventricular diastolic function and filling pressures 
Diastolic dysfunction of the left ventricle is common in critically ill patients. The 
presence of diastolic dysfunction in myocarditis has been described in lymphocytic myocarditis 
as described by James et al (36), an abnormal diastolic filling pattern was seen in 29 of the 30 
patients (97%) studied. A restrictive pattern of diastolic dysfunction predominated. In acute 
myocarditis due to cardiotropic viral pathogens, Escher et at (37) have shown that 90% of the 
patients recover early with normal ejection fraction. However on follow up after 4-6 years they 
develop significant diastolic dysfunction.  
Identification of the presence of diastolic dysfunction and gauging its severity is useful in the 
optimization of the volume status and hemodynamic parameters. Different composite indices are 
used to assess the diastolic function. These indices are: 
1. Mitral annulus velocities on tissue Doppler: E/e' ratio 
2. Mitral inflow patterns: E/A, deceleration time, IVRT (IsoVolumic Relaxation Time) 
3. Pulmonary venous inflow patterns 
Mitral inflow patterns - E/A ratio  
The blood flow from the left atrium to left ventricle occurs in 3 stages. 
The E wave is caused by the initial rush of blood, when the valve opens causing a peak velocity 
in early diastole. A period of low or no flow occurs after this which is known as diastasis. The A 
wave occurs in end- diastole when the contraction of atrium causes a final rush of blood into the 
ventricle. Studying the movement of the anterior mitral leaflet in M-mode is the best way to 
assess these parameters; and is best done with Pulsed wave Doppler (PWD). In the apical 2 or 4 
chamber view the PWD cursor is placed, between the tips of the open mitral 
leaflets.
    
Figure 3 Mitral valve inflow patterns – Normal Inflow pattern 
The mitral inflow wave patterns are obtained on PWD and image is frozen. The E wave velocity 
is obtained by measuring the height of E wave, which is done after selecting "E" under "mitral 
valve" in the calculations menu. 
 The E/A ratio is calculated automatically by most echo machines. 
This is summarized in Figure 5 and 6. 
 Figure 4 – MEASUREMENT OF THE E VELOCITY 
 
Figure 5 - MEASUREMENT OF A VELOCITY 
DECELERATION TIME (DCT) 
The wave pattern of mitral inflow is obtained.DCT is selected under the ―Mitral Valve‖ from the 
calculations menu. The cursor is placed on the peak of E wave. On pressing select, a cursor point 
will appear which is then connected to the first line. Following this the cursor point is pulled to 
the bottom line (base).The line which joined the two points will align itself, with the down slope 
of E wave. The machine will now automatically calculate the deceleration 
time.
 
Figure 6 – DECELERATION TIME- Marking the slope of E wave to measure DCT 
Mitral annular Velocity - E/e' ratio 
By applying the tissue Doppler, the peak velocities of the mitral annulus in diastole are 
measured. It is done both both medially and laterally. These velocities are marked as e' (medial) 
and e' (lateral).After acquiring the A4C view, PWD is selected. Tissue Doppler imaging (TDI) is 
switched on. In the base of mitral leaflet over the medial mitral annulus, a sample volume of 2-
mm to 5-mm is placed. 
 Figure 7 MEASUREMENT OF E/e' - TDI cursor placed on the medial mitral annulus 
In diastolic phase 2 negative waves and in systolic phase 1 positive wave is seen. The first wave 
of diastole is because of the movement of the mitral valve annulus towards the left atrium which 
occurs during the initial filling phase of the left ventricle. This wave is called as e'. The second 
wave of diastole  is called as a'. The systolic wave is labeled s'. 
After acquiring the waveform by freezing the screen, "e' (medial)" under "TDI" which is seen in 
the calculations menu is selected. The peak e' velocity is measured with the cursor.  
 Figure 8- Measurement of e' on the medial annulus tissue Doppler trace 
 
GRADING OF DIASTOLIC DYSFUNCTION 
Grade 1: Normal filling pressures with impaired relaxation 
Grade 1a: Elevated filling pressure with impaired relaxation pattern. 
Grade 2: Pseudo normalized pattern 
Grade 3: Restrictive pattern with reversibility 
Grade 4: Irreversible restrictive pattern 
Grade 1 diastolic dysfunction (Impaired myocardial relaxation) 
The first abnormality in diastolic dysfunction, due to any cause, is the decrease in 
myocardial relaxation. The common causes are left ventricular hypertrophy, increasing age and 
myocardial ischemia. The Dct (>240 sec) is prolonged with  E/A ratio < 1. In tissue Doppler 
assessment, the E/e' ratio (medial) <8, with reduced e' suggesting a normal LA pressure. 
The wave of pulmonary venous inflow called D wave has small amplitude than S wave. The AR 
wave is normal. 
Grade 1a diastolic dysfunction (Impaired myocardial relaxation with elevated filling pressures) 
The pattern resembles Grade 1.However E/e' ratio (medial) is > 15, suggestive of a high LA 
pressure.  
Grade 2 diastolic dysfunction (Pseudo normalized pattern) 
Deterioration of the diastolic LV function causes a decrease in LV compliance leading to 
increase of LA pressure as well as the diastolic filling pressure. The E wave velocity in the 
transmitral part increases progressively which causes decrease in Dct. As it happens, it goes 
through a stage which simulates a normal filling pattern causing E/A ratio to vary between 1 and 
2 and the Dct between 160 and 240ms.This is called as pseudo-normal pattern, which is a pattern 
of transition from improper relaxation to restrictive filling. This is a resultant effect of increased 
LA pressure superadded on a relaxation abnormality. 
The following clues help to differentiate this from a normal filling pattern 
1) Pulmonary venous flow AR >25cm/sec, and greater than transmitral A wave. 
2) E/e' ratio (medial) >15. 
3) Presence of LA enlargement or LV hypertrophy. 
Grade 3 and 4 diastolic dysfunction (restrictive pattern) 
As the severity of diastolic dysfunction increases, the compliance of left ventricle reduces 
and LA pressures increases. The low compliance of the LV leads to a fast increase in the early 
Left ventricular pressure. This causes shortening of the inflow and deceleration time. The Dct is 
< 160ms and E/A ratio is > 2.The high LA pressure leads to an E/e' ratio >15 at the medial 
annulus. A flow reversal occurs in pulmonary vein as the forward diastolic pulmonary vein flow 
stops in mid-late diastole and during atrial contraction, leading to a prolonged AR. 
Reduction of preload by performing Valsalva maneuver or by administration of nitroglycerine 
leads to a reversal to grade 1 or 2, which indicates that there is reversibility of the cardiac 
restriction and is termed as grade 3. 
If this reversal is absent, diastolic filling becomes irreversible (grade 4). 
                   
 
Figure 9 - Representation the different diastolic filling patterns 
                              http://www.fac.org.ar/scvc/llave/echo/roeland/roelandi.htm 
Left atrial pressure (LAP) 
Elevation of left atrial filling pressures is a characteristic of heart failure. In order to 
optimize therapy in management of cardiac failure and to predict prognosis as well as to assess 
disease status at follow up, determination of LAP is required. Pulsed wave Doppler 
echocardiography is an effective practical tool for non-invasive assessment of left atrial 
pressures.  
In patients with atrial fibrillation, cardiac allograft, sinus tachycardia as well as in normal 
subjects, E/e‘ ratio has been applied successfully to estimate left ventricular filling pressures. An 
E/e >10 estimates a pulmonary wedge pressure of > 12mm of Hg(38). A E/e <8 indicates normal 
pressure and E/e >15 implies high pulmonary wedge pressure (39). 
The formula to calculate LA pressure:  
Sinus rhythm- 2+1.2(E/e') 
Sinus tachycardia -1.5+1.5(E/e') 
Atrial fibrillation - 6.5+0.8(E/e') 
The E/e' is obtained from the medial mitral annulus. 
Assessment of LV systolic function 
Ejection fraction [EF] 
The end diastolic left ventricular volume (LV) in percentage, measured as the volume 
which is ejected from left ventricle during contraction(systole) is called as Left ventricular 
ejection fraction (LVEF).50% and above is considered normal. This is used as an indicator of LV 
systolic function (contractility).The common methods used to assess EF are the M-mode, 2-D 
and the 3-D echocardiography. 
M-mode LV dimensional method 
In M mode echocardiography, the EF is measured as a percentage which is obtained from 
the middle part of left ventricular diameters. This is measured in end of diastole and systole. It is 
noted as fractional shortening or LV shortening. In the parasternal long axis (PLAX) view, a M-
mode cursor is kept over the septal and posterior LV walls, which is on the tip of the mitral 
leaflets. In the M-mode measurements, the internal dimensions of RV, thickness of inter - 
ventricular septum, internal LV dimension and LV thickness of the posterior wall at end-diastole 
(timed on ECG or largest LV internal dimension) and at end-systole (ECG timed or smallest LV 
internal dimension) are taken. 
 
 Figure 10 - Systolic measurement in parasternal long axis (PLAX) view 
 
Figure 11- Diastolic measurement in parasternal long axis (PLAX) view 
Machines will derive the ejection fraction and fractional shortening based on the measurements. 
The difference between the left ventricular end diastolic diameter (LVEDd) and the left 
ventricular end systolic diameter (LVESd) over LVEDd is called fractional shortening which is 
expressed as a percentage. The normal value ranges between 30% to 45%.  
"Cubed" or "Teichholtz" equations uses derived volumes which can be used to calculate ejection 
fraction: 
Cubed equation - V m3 = D3 where: 
V m3= volume (cm3) from cubed M-mode calculation D = M-mode LV dimension (cm) 
Teichholz formula: V mt = [(7.0/2.4)+D] (D3) 
[V mt = volume (cm3) from M-mode Teichholz calculation] 
 
In a diseased ventricle, the usefulness of this is limited in view of the multiple geometric 
assumptions. In dilated and spherical ventricles, there is a potential over estimation of left 
ventricular volumes because the ratio of long to short axis in the ventricle increases.  
The derived formula by Teichholz compensates for ventricles with size abnormality but only in 
the absence of regional wall motion abnormalities. The normal ejection fraction in M mode 
ranges betweens 50% to 75%. 
There are multiple drawbacks in EF calculation using the M-mode. The M-mode assessment 
provides contractility assessment along a single line. In a patient with ischemic heart disease 
with regional wall motion abnormalities, LV dysfunction severity can be underestimated, if only 
a normal region is assessed or overestimated if the beam transits through the areas where 
regional wall motion anomalies occur.  
Another potential disadvantage of the M-mode assessment is that it does not represent the true 
minor axis dimension. This occurs commonly in elderly patients and emphysematous patients. In 
these patients there occurs angulation in the interventricular septum which leads to the M-mode 
beam traversing the ventricle in a tangential manner causing overestimation of the true internal 
dimension.  
Volume status and preload responsiveness assessment 
Central venous pressure (CVP) as an estimate of inferior venacava (IVC variability)  
Assessment of volume status is important in guiding management of a haemodynamically 
unstable patient. Determination of the nature of shock is also important. Monitoring central 
venous pressures for assessing fluid status is currently being replaced by newer ultrasound 
guided techniques. Studies comparing the ultrasound techniques with central venous pressure 
monitoring showed a good correlation in both mechanically ventilated and non ventilated 
patients. This proves that ultrasound guided techniques are a better non invasive tool in assessing 
the volume status compared to other methods. 
Echocardiography of the IVC is done using the transthoracic approach at the subcostal 
level. The transducer is placed below the xiphisternum at 1-2 cms to midline on the right side. 
The marker is kept pointing towards the notch of the sternum. A 2 dimensional image of the 
Inferior venacava, entering the right atrium is obtained. About 1 – 2 cms from the junction of 
IVC with the right atrium, an M mode line is placed and the image is obtained. The maximum 
and the minimum diameter of the IVC trace is obtained.  
This is summarized in Figure 13. 
 Figure 12 – Measurement of the maximum and minimum diameters in a M-mode tracing 
of the IVC showing marked IVC variability. 
 
Figure 13 – Measurement of the maximum and minimum diameters in a M-mode tracing 
of the IVC showing insignificant IVC variability 
IVC diameter 
When the IVC diameter (IVCD) becomes smaller than 1 cm a low CVP value is obtained 
and when the diameter increases more than 2 cm, an abnormally high CVP is obtained. A wide 
variation however exists. With application of positive pressure ventilation the absolute 
measurements are not applicable. The IVC size indicates the volume status but will not provide 
information on volume responsiveness, which are two different entities. 
A virtual IVC is a completely collapsed IVC which is difficult to be visualized. If this occurs in a 
mechanically ventilated or spontaneously breathing patient, it suggests severe volume depletion 
with no associated absence of raised intra-abdominal pressure. 
IVC collapsibility index 
Studying the variation of IVC diameter in different phases of respiration will help in 
differentiating normal subjects from those patients who have raised right atrial pressure. In a 
healthy spontaneously breathing subject, variations in pleural pressure occur cyclically. This is 
transmitted to the right atrium which produces cyclic variations in venous return. These 
variations increase with inspiration causing an inspiratory decrease of about 50% in IVC 
diameter. 
 
Figure 14 - IVC Variability – Normal subjects 
The IVC collapsibility index is the difference between the value of the maximum and the 
minimum diameter. This is divided by the maximum of the two values. The maximum diameter 
is used as the denominator. This index is valid for spontaneously breathing patients not requiring 
mechanical ventilation. This can be used as an indicator of volume status (hypovolemic, 
hypervolemia) and right atrial pressure; however it cannot be used as indicator of volume 
responsiveness. IVC Collapsibility index helps in estimation of CVP non-invasively and also has 
been studied as a tool to monitor fluid removal during hemodialysis and ultra filtration. 
 
Figure 15 – IVC Variability – Ventilated patients 
In a patient on mechanical ventilation, the inspiration causes the pleural pressure to 
increase, which is subsequently transferred to the right atrium. This in turn reduces the venous 
return. This leads to a reversal in the cyclic changes of the IVC diameter causing a rise in the 
inspiratory phase with a drop in the expiratory phase. These variations are observed only with 
normal right atrial pressures. In a patient with signs of hypovolemia or circulatory insufficiency 
more variations occur. In a patient receiving mechanical ventilation, measuring the diameter of 
IVC will not be an accurate predictor of the right atrial pressure and lack of respiratory variations 
in a patient with signs of circulatory insufficiency indicates that volume expansion will not be of 
benefit in 90% of the situations. ΔIVC is a quantification of this variation, calculated by 
measuring the difference between the maximum and minimum diameters on the M-mode and 
dividing it by the mean of the two. The denominator here is the mean diameter. 
In a patient on mechanical ventilation, a variation more than 12% indicates that these 
subjects would show response to volume expansion (filling) by means of increase in the cardiac 
output when compared to those who would not show any response. This has a 93% of positive 
predictive value with a negative predictive value of 92%. The measurements must be taken 
during ventilator breaths (mandatory). The tidal volume should be a minimal of 8 ml/kg and the 
patient should be in sinus rhythm to assess this parameter. 
Distensibility index is another index, and it differs from ΔIVC in that the denominator 
used is the minimum diameter. The cutoff value for this index is 18%.The normal IVC variation 
in a spontaneously breathing patient is 50%. These two indices mentioned above are not reliable 
in spontaneously breathing patients.  
This technique is a dynamic and a noninvasive parameter. It evaluates the benefits of volume 
expansion. The examination of the IVC is easy and it can be done by someone with limited 
experience in echocardiography.  
 
 
 
Relating IVC measurements and CVP: 
In spontaneously breathing patients: 
IVC diameter Collapse CVP 
<1.0cm 
 
complete collapse 5 cms 
1-2cms 
 
> 50% collapse 10 cms 
1-2cms 
 
< 50% collapse 15 cms 
> 2cms 
 
0-50% 20 cms 
>2cms 
 
no change 25 cms 
 
In ventilated patients with no spontaneous breaths: 
IVC diameter Collapse CVP 
<1.0cm 
 
complete collapse 5 cms 
1-2cms 
 
> 18% collapse 10 cms 
1-2cms 
 
< 18% collapse 15 cms 
> 2cms 
 
0-18% change 20 cms 
>2cms 
 
no change 25 cms 
4.10.5 Myocarditis in Scrub Typhus 
 
The cardiac manifestations in scrub typhus have not been well studied. There are case 
reports and small case series on myocarditis complicating scrub typhus infection. Sittiwangkul et 
al (35) in his series of 4 patients with scrub typhus presenting with fulminant myocarditis, all 4 
of them had evidence of myocarditis in the form of elevated cardiac enzymes and myocardial 
dysfunction (low left ventricular ejection fraction). All 4 were on multiple vasoactive supports 
and 2 of the 4 succumbed to the illness. Myocarditis in scrub typhus in pediatric population has 
been studied in south India, Kumar et al (40) in his cohort of thirty five children myocarditis was 
diagnosed if features of: 
(i) Congestive cardiac failure or cardiomegaly  
(ii)Haemodynamic compromise that required a vasopressor (≥5g/kg/min of dobutamine or 
dopamine) 
(iii)Left ventricular dysfunction identified by echocardiography without previous 
cardiomyopathy 
(iv) Elevated CPK-MB levels in the blood, with or without ECG abnormalities. 
 Hypotension was defined as a systolic blood pressure below the 5th percentile for the 
corresponding age, sex and height. The incidence of myocarditis in this series was 34% (40).  
 
 
 
 
4.10.6 OTHER RICKETTSIAL ILLNESSES 
The myocardial dysfunction has been extensively studied in patients with Rocky 
Mountain spotted fever (RMSF) caused by Rickettsia rickettsia transmitted by the ticks, endemic 
in south Atlantic and south American states. In patients with RMSF, enlargement of left ventricle 
was noted however the ventricular function was preserved. Myocarditis was a common finding at 
the autopsy studies. Myocardial edema was evident through increased weight of the heart, in 
eight of nine cases and increased volume of the interstitium, in six out of nine autopsied cases. 
 Rickettsia rickettsii was demonstrated in myocardium through immunofluorescent staining of 
myocardial capillaries, venules, and arterioles. The demonstration of the organism correlated 
well with the patchy distribution of interstitial mononuclear myocarditis in eight out of the nine 
cases. This provides the evidence of the pathogenic mechanism for vascular injury-induced 
myocardial edema. 
5. METHODOLOGY      
 
5.1 STUDY DESIGN 
Prospective cohort study of patients admitted with scrub typhus infection. 
5.2 SETTING 
This study was conducted in the Christian Medical College and Hospital, a 2695 bedded teaching 
institute in south India. The hospitalized patients from medical wards, medical intensive care unit 
and medical high dependency unit were included in the study.  
5.3 DURATION OF THE STUDY 
The study period was for 20 months from June 2012 to January 2014 (including the two rainy 
seasons-the peak time for scrub typhus). 
5.4 STUDY PARTICIPANTS 
All adult patients admitted from accident and emergency department or from the outpatient clinic to the 
general medical wards, medical high dependency unit and intensive care unit with acute febrile illness. 
(Annexure no.1) 
5.5 ELIGIBILITY CRITERIA 
5.5.1 Inclusion criteria 
1) Age more than 16 years. 
2) Acute febrile illness (AFI) with criteria fulfilled for the diagnosis of scrub typhus.  
3) Absence of any obvious focus of infection after initial clinical evaluation. 
5.5.2 Exclusion criteria 
1) Alternative diagnosis other than scrub typhus. 
2) Patients diagnosed with autoimmune disorders. 
5.5.3 Diagnostic criteria for scrub typhus 
A diagnosis of scrub typhus was made on the following criteria: 
1. Acute febrile illness and the presence of a positive scrub IgM ELILSA or eschar, or 
2. Acute febrile illness and a positive scrub IgM ELISA seroconversion on convalescent sera, or 
3. Acute febrile illness and a positive scrub IgM ELISA with other serologies negative 
5.5.4 Withdrawal criteria 
1. Patients unwilling to consent and further participation in the study. 
5.6 OUTOME MEASURES 
5.6.1 Primary outcome and definitions 
The primary outcome was the number of patients with myocarditis attributable to scrub typhus 
infection and other causes excluded. –. 
1. Myocardial injury was defined as elevation in troponin T level (more than 14pg/ml). 
2. Myocardial dysfunction (left ventricular) was defined as reduced ejection fraction (less 
than 50%) in M mode parasternal long axis view. 
3. Myocarditis was presumed when myocardial injury was associated with global 
myocardial dysfunction in the setting of an acute febrile illness due to scrub typhus 
infection. 
5.6.2 Secondary outcomes 
1. Mortality  
2. Duration of hospital stay  
3. Need for ventilation 
4. Duration of ventilation 
5. Use of vasoactive agents (shock) 
6. Comparison of mortality and survival analysis in patients with evidence of myocarditis 
with patients who did not have myocarditis.  
5.7 Confounders considered pre hoc 
1. Pre-existing cardiac disease 
2. Sepsis  
3. Renal failure 
4. Ventilation  
5. Use of vasoactive agents  
5.8 SAMPLE SIZE  
Sample size calculation was based on an assumption of prevalence of myocarditis of 30% in 
patients with scrub typhus infection. All adult patients admitted with acute febrile illness (AFI) 
with criteria fulfilled for the diagnosis of scrub typhus, between June 2012 and March 2014 were 
included in the study and evaluated for myocarditis. The sample size required to show the 
prevalence of myocarditis in scrub typhus as 30%, with 10% precision was calculated using the 
formula: 
 
 
 
This was calculated to be 84. 
5.9 Source of information 
1. Detailed clinical history and through general physical examination of the study 
participants  
2. Study participants relatives 
3. Laboratory testing  
4.  Echocardiography 
5.10 Validation  
The principal investigator underwent training in echocardiography by a trained critical care 
sonologist. Transthoracic echocardiography was performed with a Sonosite Micromax unit using 
a 1 to 5MHz phased array transducer probe. To reduce inter-observer variation in 
echocardiography findings, a validation study was done. Twenty patients were chosen randomly 
and echocardiography was done individually by the principal investigator and Dr. Kishore 
Pichamuthu (trained critical care sonologist) and inter-observer variation was measured using 
kappa and interclass correlation coefficient. 
5.10.1 The Kappa Statistics 
When two or more independent observers are evaluating the same variable, inter-observer 
variation can be measured. The calculation is based on the difference between the agreement 
which is actually present (―observed‖ agreement) compared to agreement which would be 
expected to be present by chance alone (―expected‖ agreement). Kappa is a statistic parameter 
which measures this difference. This is a scale standardized to lie between -1 to +1. (1 is perfect 
agreement and 0 is what would be expected by chance, and negative values indicate agreement 
less than by chance where there is systematic disagreement between the observers). 
5.10.2 Interpretation of Kappa 
 
Kappa Agreement 
< 0 Less than chance agreement 
0.01-0.20 Slight agreement 
0.21-0.40 Fair agreement 
0.41-0.60 Moderate agreement 
0.61-0.80 Substantial agreement 
0.81-1.00 Almost perfect agreement 
Table 1 INTERPRETATION OF KAPPA 
 
 
Table 2 showing validation study on 20 patients, for binary variable Kappa was used to measure 
degree of agreement and for quantitative variables interclass correlation coefficient was used to 
determine the degree of agreement.  
Variable Kappa value Interclass correlation 
coefficient 
Regional wall motion abnormality # 0.57 - 
Left ventricular ejection fraction * - 0.76 
E/a * - 0.86 
Left ventricular outflow tract * - 0.87 
IVC variability * - 0.76 
E/e‘ * - 0.88 
E/A- mitral valve annulus measured in apical 4 chamber view, E/e‘- medial mitral valve 
annulus measured using tissue Doppler, IVC- inferior venacava. 
# - binary variable, hence kappa value used. 
* - quantitative variable, hence interclass correlation coefficient. 
Table 2 STUDY VALIDATION 
5.11 Data collection   
A proforma (Annexure 2) was made containing all data required for analysis. This was filled by 
the principal investigator on the day of admission and updated daily till discharge from the 
hospital or till the patient expired. The proforma enclosed contained all data required for analysis 
including the echocardiography parameters. The collected data was entered in Microsoft excel 
spread sheet which was password protected. The data was collected in the following categories 
specifically. 
5.11.1 Non cardiac parameters 
1. Baseline demographics: age, gender, hospital number, height, weight (where feasible), 
place and duration of illness. 
2. Co-morbid illness: diabetes mellitus, hypertension, coronary artery disease, valvular heart 
disease, smoking, alcohol consumption, autoimmune condition and chronic 
immunosuppressant use.  
3. Symptomatology: presence of fever, cough, dyspnoea, myalgia and altered sensorium. 
4. Laboratory parameters: creatinine, total and differential WBC counts, platelets count and 
blood lactate. 
5. Variables necessary for computing SOFA score and APACHE II score. 
6. Use of different vasoactive agents  
7. Ventilation parameters: need for ventilation, type of ventilation and duration of 
ventilation. 
8. Duration of hospital stay 
9. ICU and hospital outcome  
5.11.2 Cardiac parameters 
1) Electrocardiography: Arrhythmias (sinus tachycardia or bradycardia, other supraventricular 
and ventricular arrhythmias), ST-T changes, QRS abnormalities 
2) Cardiac enzymes: CKMB and troponin T were used as specific cardiac biomarkers of 
myocardial injury 
3) Echocardiogram: To assess cardiac function (left and right ventricular), regional wall motion 
abnormalities, measure of filling status (refer table 3) 
5.11.3 Derived variables from ECHO parameters 
Systolic function of the heart was assessed by using cardiac index, ejection fraction (EF) and the 
stroke volume index (SVI). EF was calculated in the parasternal long axis view by using the M 
mode. 
The left ventricular outflow diameter was obtained using the parasternal long axis view and the 
velocity of the outflow tract was measured at the left ventricular outflow tract using Doppler 
probe in the apical 5 chamber view. The cardiac index and SVI were determined with these 
parameters. 
Left ventricular systolic dysfunction was diagnosed in patients with EF less than 50%.  
Diastolic dysfunction was diagnosed in patients with E/A lower than 1, and in patients with 
diastolic dysfunction an E/e‘ lower than 15 was considered as mild diastolic dysfunction and 
more than 15 was considered as severe diastolic dysfunction. 
CARDIAC VARIABLES MEASURED BY ECHOCARDIOGRAPHY 
 
Stroke volume index (SVI) Cardiac index/heart rate ml/beat.m2 
 
Cardiac index (CI) Cardiac output/ BSA 
 
Cardiac output (CO) Stroke volume x heart rate 
 
Stroke volume (SV) 0.785 x D
2 
x VTI 
 
left ventricular stroke volume index 
(LVSVI) 
(MAP-LAP)* SVI *0.0136 gm.m/m2/beat 
 
Systemic Vascular Resistance Index (SVRI) ((Map-CVP)/CARDIAC OUTPUT)*80 
dyne.sec/cm 
 
Left Atrial Pressure (LAP) In sinus rhythm: 2+1.2(E/e‘) 
 
Sinus tachycardia: 1.5+ 1.5(E/e‘) 
 
Atrial fibrillation: 6.5 + 0.8(E/e‘) 
D-left ventricular outflow tract diameter, VTI-velocity time integral, measured in the LVOT 
proximal to the aortic valve, BSA- basal surface area. 
Table 3 CARDIAC VARIABLES MEASURED BY ECHOCARDIOGRAPHY 
ASSESSMENT OF QUANTITATIVE VARIABLES 
Quantitative variable under study Analysis  
APACHE II Score on admission Calculated on enrolment 
SOFA Score Calculated on enrolment 
Duration of fever Necessary for estimation of duration of 
infection 
Vital signs (heart rate, temperature, blood 
pressure, respiratory rate.) 
Necessary for calculation of APACHE II and 
SOFA score 
Liver function test, PT and albumin Necessary for calculation of SOFA score and 
evaluation of liver function  
Creatinine, sodium, potassium, urea Necessary for calculation of SOFA score and 
evaluation of renal function 
Arterial pH, pO2, pCo2 Necessary for calculation of APACHE and 
SOFA score 
Haemoglobin, total counts, platelet counts. Necessary for calculation of APACHE II and 
SOFA Score and for evaluation of 
haematological function 
Vasoactive agent use Necessary for calculation of vasopressor score 
and SOFA score 
CKMB, Troponin T Necessary for evaluation of cardiac 
involvement  
Echocardiography findings(LVEF, CI, E/e‘, 
LAP) 
Necessary for evaluation of cardiac 
dysfunction 
Table 4  ASSESSMENT OF QUANTITATIVE VARIABLES 
 
 
5.12 STATISTICAL METHODS 
Statistical analysis was done using SPSS version 15 and Stata 11® statistical package 
(Statacorp, college station, Texas, USA). Descriptive statistics were obtained for all variables in 
the study. Categorical and continuous variables were compared for outcome by using the fisher‘s 
exact test and student t test respectively. All continuous data were expressed as mean ± SD 
unless the data was not normally distributed. A p value of < 0.05 was considered statistically 
significant for all analysis. The presence of myocarditis, myocardial injury and dysfunction were 
correlated with mortality. This was expressed as odds ratio (OR) with 95% confidence interval 
(CI). A multivariate logistic regression analysis was performed to assess and identify those 
factors which were independently associated with myocarditis. 
5.13 FUNDING 
Fluid research grant, Christian Medical College 
5.14 INSTITUTIONAL RESEARCH BOARD APPROVAL AND ETHICAL 
CONSIDERATIONS: 
In this observational cohort study there were no ethical issues. The study was explained to the 
participants/relatives and a written and informed consent was obtained before measuring cardiac 
enzymes and echocardiography. Institutional Research Board (IRB) approval was obtained (IRB 
Min. No. 8104 dated 05.12.2012).  
6. RESULTS 
6.1 PARTICIPANTS 
This prospective cohort study was conducted over a period of 20 months (June 2012 to January 
2014) in a teaching institution in South India. 
 Acute febrile illness due to various causes is most commonly seen during the months of rainy 
season in south India.  
One hundred and twenty two patients with acute febrile illness who fulfilled the inclusion criteria 
were screened for myocarditis. On further evaluation and on using the diagnostic criteria, 19 
patients were excluded as they had other etiologies for their febrile illness, 8 patients were 
diagnosed with dengue, 6 were diagnosed as undifferentiated febrile illness, 2 patients had 
enteric fever,  and spotted fever, H1N1 infection and menigococcal menigitis were diagnosed in 
the other three patients. Twenty-two patients who were diagnosed as scrub typhus were 
excluded, of which 19 patients were excluded due to poor echo widow resulting in inadequate 
echocardiography data and 3 patients were excluded due to refusal to consent for the study. The 
remaining 81 patients diagnosed with scrub typhus were followed up till discharge / death for 
further analysis. 
 6.2 STUDY FLOW CHART 
 
Number of AFI screened(n-122) 
 
Dengue- 8 
Acute Undifferentiated Febrile 
Illness- 6 
Enteric fever- 2 
H1N1 Influenza- 1 
Meningococcal meningitis – 1 
Spotted fever- 1 
 
AFI DUE TO OTHER CAUSES 
 (n = 19) 
Number of Scrub typhus patients screened (n – 102) 
*EXCLUSION (n - 22) 
Withdrawal of consent (n – 3) 
Inadequate echo data due to poor 
window (n -19) 
 
 
Included cases of Scrub Typhus
# 
(n – 81) 
MYOCARDIAL DYSFUNCTION 
(n – 25) 
MYOCARDIAL INJURY 
(n – 50) 
SCRUB TYPHUS PATIENTS WITH 
MYOCARDITIS 
(n - 17) 
 6.3 PATIENT DEMOGRAPHICS 
The study cohort comprised of 81 patients with a mean ± SD age of 49.41 ± 16.07 and presenting 
at 8.11 ± 3.11 days of illness.  
The study population represented scrub typhus patients from south India, predominately from 
Tamil Nadu (65%) followed by Andhra Pradesh (35%). 
There was a slight female predominance observed, with female: male ratio of 1.3:1. 
Table 5 BASELINE CHARACTERISTICS 
BASELINE CHARACTERISTICS OF THE STUDY PARTICIPANTS (N-81) 
Variable Value 
Age, mean ± SD years 49.41 ± 16.07 
Gender ratio (female/male) 46:35 
Day of presentation from onset of illness, mean ± SD) days 8.11 ± 3.11 
State wise distribution, number (%) 
Tamil Nadu 53 (65.4) 
Andhra Pradesh  28 (34.6) 
 
                                       
 
Figure 16- GENDER DISTRIBUTION OF SCRUB TYPHUS 
                                                 
 
Figure 17 – STATEWISE DISTRIBUTION OF SCRUB TYPHUS 
 
 6.4 SYMPTOMATOLOGY OF PARTICIPANTS 
All patients in the cohort had fever as the presenting complaint, followed by dyspnea which was 
seen in 52(76.5%) patients followed by myalgia in 30 (37%) patients and cough in 29 (35.8%) 
patients. Vomiting and altered sensorium were less commonly seen in this cohort of patients 
(27.2% and 18.5% respectively). 
Table 6 – SYMPTOMATOLOGY OF PATIENTS WITH SCRUB TYPHUS 
SYMPTOMATOLOGY OF PATIENTS WITH SCRUB TYPHUS (n-81) 
Variable Frequency- n (%) 
Fever  81 (100) 
Cough  29 (35.8) 
Breathlessness  52 (76.5) 
Altered mental status 15 (18.5) 
Myalgia  30 (37) 
Vomiting 22 (27.2) 
 
 
       
                                         
 
 
 
 
 
 
  
       
Figure 18 – SYMPTOM PROFILE OF PATIENTS WITH SCRUB TYPHUS 
 
       
 
 
 
 
 
6.5 CO-MORBID ILLNESS IN PARTICIPANTS: 
The underlying co-morbid illness are summarized below, Diabetes mellitus was the most 
common co-morbid condition which was seen in nearly one fifth of the study population (n-19), 
followed by hypertension seen in 15 (18.5%) patients. Five patients were pregnant and two had 
coronary artery disease. The number of patients with smoking and alcohol consumption was 
relatively low in the study group (3 and 4 patients respectively). There was one patient each with 
HIV infection and dyslipidemia. There was no patient in this entire cohort with history of 
autoimmune condition, long term immunosuppressive therapy, and hematological malignancy or 
platelet disorders.                        
Table 7 COMORBID ILLNESSES IN PATIENTS WITH SCRUB TYPHUS 
CO-MORBIDITIES IN PATIENTS WITH SCRUB TYPHUS- (n-81) 
Co-morbid illness Frequency (%) 
Diabetes  16 (19.7) 
Essential hypertension 15 (18.5) 
Pregnancy  5 (6.1) 
Coronary artery disease 2 (2.4) 
Smoking  3 (4.6) 
Alcohol  4 (6.2) 
 
 
                        
 
 
 
                    
Figure 19 – PROFILE OF COMORBID ILLNESS IN PATIENTS WITH SCRUB 
TYPHUS 
 
 
 
 
 
 
 
HTN-hypertension 
CAD- coronary artery disease 
6.6 CLINICAL SIGNS- ESCHAR 
The presence of a classical eschar is of diagnostic significance; an eschar was seen in 62 (77%) 
of patients. Of the 62, 61 patients were scrub IgM Elisa positive, one patient was diagnosed on 
the basis of an eschar alone. 
             
 
Figure 20 – PRESENCE OF ESCHAR IN PATIENTS WITH SCRUB TYPHUS 
 
 
Figure 21 - ESCHAR 
6.7 LABORATORY PARAMETERS 
In this cohort of patients, the mean hemoglobin was 11.45 gm%. These patients had a mild 
elevation in their total counts with a mean of 10400 / cmm. Thrombocytopenia (platelet count 
less than 1.5 lakhs) was observed in 92.6% of patients with a mean platelet count of 69700/ cu 
mm. There was mild derangement in renal function in these patients with a mean creatinine of 
1.71 mg %. The liver function test showed mild decrease in albumin, mean of 2.58 gm%. There 
was a mild increase in liver enzymes; both SGOT and SGTPT were elevated, mean of 139.05 
and 68.65 respectively. The elevation in SGOT was more than the SGPT. 
LABORATORY PARAMETERS IN PATIENTS WITH SCRUB TYPHUS (n-81) 
Laboratory parameters Mean SD 95 % CI 
Hemoglobin, gm % 11.45 2.56 4.0 - 20.4 
Total counts, cmm 10400 4825.11 2700 - 30400 
Platelets, cmm 69700 70372.34 4000 - 364000 
Creatinine, mg % 1.71 1.43 0.4 - 8.1 
Total bilirubin, mg % 2.06 1.92 0.3 - 9.6 
Direct bilirubin, mg % 1.55 1.71 0 - 9.0 
Serum albumin, gm % 2.58 0.58 0.5 - 4.1 
SGOT, U/L 139.05 92.39 28 - 428 
SGPT, U/L 68.65 49.32 10 - 366 
Alkaline phosphatase, U/L 199.14 107.01 43 - 593 
SGOT-Serum Glutamic –Oxaloacetic transaminase, SGPT- Serum Glutmic Pyruvic 
Transaminase. 
Table 8 LABORATORY PARAMETERS IN PATIENTS WITH SCRUB TYPHUS 
6.8 SCORING SYSTEM AND ORGAN DYSFUNCTION 
Scrub typhus causes multiorgan dysfunction, the various organs involvement was characterized 
by sequential organ failure assessment (SOFA) and APACHE II score. The mean ± SD of SOFA 
and APACHE score were 8.94 ± 3.95 and 15.68 ± 7.01 respectively. The predicted mortality was 
calculated based on APACHE II score was 25.25%. 
SCORING SYSTEM AND ORGAN DYSFUNCTION IN SCRUB TYPHUS (n-81) 
Scoring system mean SD 95% CI 
SOFA score 8.94 3.95 8.06- 9.81 
APACHE II score 15.68 7.01 14.13-17.23 
Predicted mortality based on 
APACHE II 
25.25 18.59 22.14-30.37 
SOFA- Sequential Organ Failure Assessment, APACHE II- Acute Physiological and Chronic 
Health Evaluation.  
Table 9 SCORING SYSTEM AND ORGAN DYSFUNCTION IN SCRUB TYPHUS 
 
THE SOFA SCORE: 
The data on organ dysfunction was available for all the patients, the median frequency of organ 
involvement based on SOFA score was 4. The hematological organ dysfunction predominated 
with 96.3% followed by respiratory system 90.1%. Cardiovascular system involvement was seen 
in 62.9%, hepatic and renal involvement was present in 54.3% and 53.1% respectively. The 
central nervous system involvement was seen in only 18.5%. 
 
 
PERCENTAGE OF DIFFERENT ORGAN INVOLVEMENT IN SCRUB TYPHUS (n-81) 
 
 
Figure 22 ORGAN DYSFUNCTION IN SCRUB TYPHUS 
 
On the basis of SOFA score, the organ involvement was classified as organ dysfunction and 
organ failure. A SOFA score of 1 or 2 was considered as organ dysfunction while a score of 3 or 
4 was considered as organ failure. 
 
 
ORGAN SYSTEM INVOLVEMENT BASED ON SOFA SCORE (n-81) 
Organ system 
involved 
Organ dysfunction n (%) Organ failure n (%) 
 
Organ involvemen n (%) 
Respiratory  44 (54.32) 29 (35.80) 73 (90.1) 
Cardiovascular  9 (11.11) 42 (51.85) 51 (62.9) 
liver 36 (44.44) 8 (9.88) 44 (54.3) 
Hematological  35 (43.21) 43 (53.09) 78 (96.3) 
CNS 9 (11.11) 6 (7.41) 15 (18.5) 
Renal  36 (44.44) 7 (8.64) 43 (53.1) 
CNS-central nervous system, SOFA- Sequential Organ Failure Assessment. 
Organ dysfunction- SOFA score 1or 2, organ failure SOFA score 3 or 4, organ involvement –
SOFA score of atleast 1 
 
Table 10 ORGAN DYSFUNCTION BASED ON SOFA SCORE    
In this cohort of patients, the mean frequency of organ involvement was 4. Seven patients (8.6%) 
had all six organ involvement, 97.5% of them had 2 or more organ involvement. 
 CATEGORATION BASED ON NUMBER OF ORGAN INVOLVEMENT IN SCRUBTYPHUS 
Number of organs involved Number of patients (%) Cumulative percentage 
One  2 (2.5) 100 
Two  10 (12.3) 97.5 
Three  27 (33.3) 85.2 
Four  16 (19.8) 51.9 
Five  19 (23.5) 32.1 
Six  7 (8.6) 8.6 
 
Table 11 CATEGORIZATION BASED ON ORGAN DYSFUNCTION 
 Figure 23 ORGAN DYSFUNCTION IN SCRUB TYPHUS 
 
6.9 CARDIOVASCULAR MANIFESTATIONS 
The various cardiovascular manifestations in scrub typhus were studied using the following 
variables: 
6.9.1 Cardiac enzymes 
 The cardiac enzymes, CKMB and troponin T were done for all participants within forty eight 
hours of admission. The mean ± SD of CK-MB and troponin T of the entire cohort were 6.69 ± 
9.4 and 83.1 ± 212.2 respectively.  
 
6.9.2 Echocardiography 
Transthoracic echo was performed on all participants. The mean ± SD LVEF was 57.59 ± 
14.16. The mean cardiac output was 4.37 ± 1.38 liters. The cardiac index and systemic vascular 
resistance were measured only on 65 patients, the mean ± SD were 2.65 ± 0.89 and 2363.47 ± 
949.35 respectively. The variables used to assess diastolic dysfunction, the mean (SD) of E/A 
and E/e‘ was 1.16 ± 0.36 and 9.77 ± 3.49 respectively. The combination of the absolute diameter 
of the IVC and the degree of collapse was used to estimate central venous pressure (CVP), the 
mean CVP was 11.25 ± 5.23 cm in this cohort of patients. 
CARDIOVASCULAR MANIFESTATIONS IN SCRUB TYPHUS (n-81) 
Characteristic Number mean SD 95 % CI 
a. Cardiac biomarkers 
CKMB 81 6.69 9.4 4.88-9.07 
Troponin T 81 83.1 212.2 36.21- 130.04 
b. Echocardiography findings 
LVEF 81 57.59 14.16 54.46-60.72 
Cardiac output 63 4.37 1.38 4.02-4.71 
Cardiac index 65 2.65 0.89 2.43-2.88 
Systemic vascular resistance 65 2363.47 949.35 2128.23-2598.71 
E/A 77 1.16 0.36 1.08-1.25 
E/e‘ 78 9.77 3.49 8.98-10.56 
CVP 76 11.25 5.23 10.05-12.44 
LVEF-Left ventricular ejection fraction, E/A- measure of mitral annulus in apical four chamber view of the heart in 
echocardiography, E/e‘- measure of mitral medial annulus in apical chamber view of the heart in echocardiography, 
CVP-central venous pressure.       
Table 12 CARDIOVASCULAR MANIFESTATIONS IN SCRUB TYPHUS 
6.9.3 Electrocardiography 
Sinus tachycardia was the most common ECG presentation, seen in 38 (46.9%) patients.  
QRS morphology changes were seen in 11 patients. ST-T changes were seen in 9 patients and 8 
patients had T wave inversions. Tachyarrhythmia was seen in 5 patients of whom 3 patients had 
atrial fibrillation, one patient with supraventricular tachycardia (paroxysmal supraventricular 
tachycardia) and one patient with wide QRS tachycardia. Bradyarrhythmia was seen in 5 
patients, all 5 patients had sinus bradycardia. 
ELECTROCARDIOGRAPHIC FINDINGS IN SCRUB TYPHUS 
Sinus Tachycardia 38(46.9) 
ST-T changes 10 (12.3) 
T wave inversion 8 (9.9) 
QRS morphology changes 11 (13.6) 
Supraventricular tachycardia 1 (1.2) 
Atrial fibrillation 3 (3.7) 
Wide QRS tachycardia 1 (1.2) 
Sinus bradyarrhythmia 5 (6.2) 
Table 13 ELECTROCARDIOGRAPHIC CHANGES IN SCRUB TYPHUS 
 
6.9.4 Pericardial effusion 
The presence of pericardial effusion was assessed in all patients in the apical four chamber view 
and the sub costal view; forty one patients (51%) of them had significant pericardial effusion. 
However none of them had severe effusion causing right ventricular collapse or requiring 
pericardiocentesis. The findings are summarized in Figure 26. 
  
               
Figure 24 Presence of pericardial effusion in patients with Scrub Typhus 
 
6.9.5 Regional wall motion abnormality 
The presence of regional wall motion abnormality (RWMA) was evaluated in all patients in the 
parasternal short axis and apical four chamber view. Twelve patients had regional wall motion 
abnormality of which 7 had evidence of myocarditis. 
 
 
6.10 OUTCOME MEASUSURES  
The outcome variables were classified as cardiac and non cardiac variables. The primary 
outcome was to look at the prevalence of myocarditis. 
6.10.1 Primary outcomes 
 The presence of myocarditis was seen in 17 patients (21%) of the study population. Twenty five 
of them had myocardial dysfunction as evidenced by left ventricular ejection fraction of less than 
fifty percent. Fifty patients (61.7%) of them had myocardial injury. Among these patients, 17 had 
myocarditis and 16 had evidence of renal dysfunction (creatinine more than 1.4mg %). The rest 
17 had elevation of troponin T without myocarditis or any obvious confounders causing an 
elevation. Diastolic dysfunction was measured by mitral inflow pattern (E/A) and mitral annulus 
velocities (E/e‘). Eighteen patients (22%) had evidence of diastolic dysfunction. 
6.10.2 Secondary outcomes 
 Forty nine patients (60.5%) required intensive care admission and 46 (56.8%) were in shock 
needing vasoactive agents. The various vasoactive agents used were dobutamine (n-16), 
dopamine (n-25), epinephrine (n-21) and nor epinephrine (n-35). The number of patients 
requiring ventilation was 48 (59.3%), 39 required invasive ventilation and 15 required only non 
invasive ventilation. Six patients required both noninvasive and invasive ventilation. Only 4 
patients in the cohort required haemodialysis. The mean ± SD duration of ICU and hospital days 
was 4.2 ± 4.4 and 9.2 ± 4.7 respectively. The overall hospital mortality which included 2 patients 
discharged at request (one patient from ICU and one patient from general ward) was 9.9%. Of 
the 8 patients, 7 were managed in the ICU care.  
OUTCOME VARIABLES IN PATIENTS WITH SCRUB TYPHUS (n-81) 
Primary outcomes 
Variable Frequency (%) 
Myocarditis  17 (21) 
Myocardial dysfunction 25 (30.9) 
Myocardial injury 50 (61.7) 
Diastolic dysfunction  18 (22.2) 
Secondary outcomes 
Needing ICU care 49 (60.5) 
Vasoactive agents (shock) 
Dobutamine 
Digoxin  
Dopamine  
Epinephrine  
Nor epinephrine  
46 (56.8) 
16 (19.7) 
14 (17.3 
25 (30.9) 
21 (25.9) 
35 (43.2) 
Needing ventilation 48 (59.3) 
Needing hemodialysis 3 (4) 
Duration of ICU stay, mean ± SD days 4.2 ± 4.4 
Duration of hospital stay, mean ± SD days 9.2 ± 4.7 
ICU mortality 7 (8.6) 
Hospital mortality 8 (9.9) 
ICU- Intensive Care Unit 
Table 14 SUMMARY OF OUTCOMES 
 
 
               
USE OF DIFFERENT INOTROPES IN SCRUB TYPHUS PATIENTS (n-81) 
 
Figure 25 VASOACTIVE AGENTS REQUIREMENT IN SCRUB TYPHUS 
               
 
Figure 26 VENTILATORY REQUIREMENTS IN PATIENT WITH SCRUB TYPHUS 
6.11 COMPARISON OF SCRUB TYPHUS PATIENTS, WITH AND 
WITHOUT MYOCARDITIS: 
The number of patients with myocarditis, in this cohort was 17 (21%), these patients were 
compared with the rest of the cohort to look for predictors for myocarditis and the difference 
among them were studied under the following groups: 
6.11.1 Baseline characteristics 
 The age and gender ratio were similar in both the groups, the duration of illness prior to 
presenting to the hospital was less in the myocarditis group when compared to patients without 
myocarditis. 
COMPARISON OF BASELINE CHARACTERISTICS: SCRUB TYPHUS WITH 
MYOCARDITIS AND WITHOUT MYOCARDITIS 
Variable With Myocarditis Without Myocarditis 
 
P value 
Age (mean ± SD)years 48.76 ±16.32 49.56  ± 16.13 0.85 
Gender ratio 
(male/female) 
7:1 28:36 1.00 
Duration of illness, 
(mean ±SD) days 
6.88 ± 2.82 8.44  ± 3.12 0.067 
From TN number (%) 9 (52.9) 44 (68.8) 0.258 
From AP number (%) 8 (47.1) 20 (31.2) 0.258 
LVEF- left ventricular ejection fraction, TN-Tamil Nadu, AP-Andhra Pradesh 
Myocarditis (patients with left ventricular ejection fraction less than 50 % and troponin T more than 14pg/ml) 
Table 15 COMPARISON OF BASELINE CHARACTERISTICS IN SCRUB TYPHUS 
PATIENTS WITH AND WITOUT MYOCARDITIS 
6.11.2 Comparison of symptomatology 
 All patients in this cohort had fever as the presenting compliant. Breathlessness was more 
commonly seen in patients with myocarditis group (82. 4%) as compared to patients without 
myocarditis (59.4%); however it was not statistically different. More patients without 
myocarditis presented with cough (n-24) 37.5% when compared with those who did not develop 
myocarditis (n-5) 29.4%. Vomiting and myalgia were more commonly seen in patents with 
myocarditis.  
COMPARISON OF SYMPTOMATOLOGY: SCRUB TYPHUS  WITH AND WITHOUT 
MYOCARDITIS (n-81) 
Symptom With Myocarditis 
Number (%) 
Without Myocarditis 
Number (%) 
P value 
Fever  17 (100) 64 (100) - 
Cough 5 (29.4) 24 (37.5) 0.584 
Breathlessness  14 (82.4) 38 (59.4) 0.389 
Altered mental status 3 (17.6) 12 (18.8) 1.00 
Myalgia  7 (41.2) 15 (23.4) 0.449 
Vomiting  7 (41.2) 15(23.4) 0.218 
Myocarditis (patients with left ventricular ejection fraction less than 50 % and troponin T more 
than 14pg/ml 
Table 16 COMPARISON OF SYMPTOMATOLOGY IN SCRUB TYPHUS PATIENTS 
WITH AND WITHOUT MYOCARDITIS 
 
 
 
 
  
 
Figure 27 COMPARISON OF SYMPTOMATOLOGY IN PATIENTS WITH AND 
WITHOUT MYOCARDITIS. 
 
6.11.3 Comparison of laboratory parameters 
 The myocarditis group had a mild elevation in hemoglobin and a slight decrease in total counts. 
The degree of thrombocytopenia was more prominent in the myocarditis group with a mean 
platelet counts of 52900 cmm as compared to 74100 cmm in the group without myocarditis. 
There was a mild decrease in creatinine and albumin levels in the myocarditis group. 
COMPARISON OF LABORATORY PARAMETERS OF SCRUB TYPHUS WITH AND 
WITHOUT MYOCARDITIS 
VARIABLE WITH MYOCARDITIS WITHOUT 
MYOCARDITIS 
P 
VALUE 
Creatinine, mean ± SD, mg % 1.55 ± 0.89 1.77 ± 1.55 0.580 
Hemoglobin, gm % 12.04 ± 3.69 11.24 ± 2.17 0.259 
Total counts, cmm 8570.59 ± 3803.24 10900 ± 4969.67 0.072 
Platelets , cmm 52900 ± 25969.86 74100 ± 77598.25 0.272 
Total bilirubin, mg % 1.62 ± 1.38 2.14 ± 2.04 0.296 
Direct bilirubin, mg % 1.23 ± 1.350 1.64 ± 1.79 0.384 
Serum albumin, gm % 2.359 ± 0.799 2.641 ± 0.505 0.077 
SGOT U/L 149.88 ± 84.22 136.17 ± 94.87 0.590 
SGPT U/L 66.76 ±  43.87 69.16 ± 50.98 0.860 
Alkaline phosphatase, U/L 194.59 ± 123.17 200.34 ± 103.35 0.845 
SGOT-Serum Glutamic –Oxaloacetic transaminase, SGPT- Serum Glutmic Pyruvic 
Transaminase. 
Table 17 COMPARISON OF LABORATORY PARAMETERS IN PATIENTS WITH 
AND WITHOUT MYOCARDITIS 
The creatinine and albumin means were 1.55mg % and 2.36 gm % in the myocarditis group, 
while in the group without myocarditis the mean creatinine and albumin were 1.77 mg % and 
2.64 gm % respectively. 
6.11.4 Comparison of scoring system and organ dysfunction 
The various organ dysfunctions were assessed using SOFA score, and APCAHE II score 
was used to predict the mortality. Patients with myocarditis had a higher SOFA and APACHE II 
score; however only SOFA score was statistically significant, the mean ± SD SOFA score in 
patients with myocarditis and without myocarditis were 10.82 ± 3.02 and 8.43 ± 4.03 
respectively. The predicted mortality in the myocarditis group was 30.24 %, in the group without 
myocarditis it was 25.19%. 
COMPARISON OF SCORING SYSTEM AND ORGAN DYSFUNCTION AMONG 
SCRUB TYPHUS WITH AND WITHOUT MYOCARDITIS 
Variable With Myocarditis    
(n-17)                    
Mean ± SD 
Without Myocarditis 
(n-64)                  
Mean ± SD 
P value 
SOFA score 10.82 ± 3.02 8.43 ± 4.03 0.026 
APACHE II 17.35 ± 7.49 15.12 ± 6.95 0.254 
Predicted mortality  30.24 ± 21.06 25.19 ± 17.91 0.323 
Table 18 COMPARISON OF SCORING SYSTEM OF ORGAN DYSFUNCTION IN 
PATIENTS WITH AND WITHOUT MYOCARDITIS 
 
 
 
Comparison of SOFA scores: 
On the basis of SOFA score the organ involvement was classified into organ dysfunction and 
organ failure, the predominant organ dysfunction seen in the myocarditis group was renal (n-9) 
52.9%, in patients without myocarditis renal involvement was seen in (n-27) 42.2%. 
Cardiovascular dysfunction was seen almost equally in both the groups, 11.8 % ( n-2) and 10.9% 
(n-7). On comparing organ failure, cardiovascular organ failure was more commonly seen in 
patients with myocarditis as compared to those without myocarditis, 82.3% (n-14) and 43.7% (n-
28) respectively and this was significantly different. 
 
COMPARISON OF ORGAN DYSFUNCTION USING SOFA SCORE: SCRUB TYPHUS 
WITH AND WITHOUT MYOCARDITIS 
Organ With Myocarditis     
(n-17)                         
n (%) 
Without Myocarditis 
(n- 64)                        
n (%) 
P value 
Respiratory  8 (47.1) 36 (56.2) 0.588 
Cardiovascular  2 (11.8) 7 (10.9) 1.00 
liver 8 (47.1) 28 (43.7) 1.00 
Hematological  6 (35.3) 29 (45.3) 0.585 
Central nervous system 2 (11.8) 7 (10.9) 1.00 
Renal  9 (52.9) 27 (42.2) 0.584 
SOFA- Sequential Organ Failure Assessment   
Table 19 COMPAISON OF ORGAN DYSFUNCTION IN PATIENTS WITH AND 
WITHOUT MYOCARDITIS 
 
 
 
COMPARISON OF ORGAN FAILURE USING SOFA SCORE: SCRUB TYPHUS WITH 
AND WITHOUT MYOCARDITIS 
Organ With Myocarditis       
n (%) 
Without Myocarditis      
n (%) 
P value 
Respiratory  9 (52.9) 20 (31.2) 0.153 
Cardiovascular  14 (82.3) 28 (43.7) 0.006 
liver 1 (5.8) 7 (10.9) 1.00 
Hematological  11 (64.7) 32 (50) 0.413 
Central nervous system 1 (5.8) 5 (7.8) 1.00 
Renal  1 (5.8) 6 (9.4) 1.00 
In Myocarditis group n- 17 and non Myocarditis group n-64 
Table 20 COMPARISON OF ORGAN FAILURE IN PATIENTS WITH AND WITHOUT 
MYOCARDITIS 
6.11.5 Comparison of secondary outcomes 
 The secondary outcomes were compared between scrub typhus patients with myocarditis (n-17) 
and without myocarditis (n-64). More patients with myocarditis (82.3%) were admitted to the 
ICU when compared with those without myocarditis (54.7%), which was significantly different. 
Scrub typhus patients with shock (requiring vasoactive agents) were more predominant in the 
myocarditis group, (94.1%) as compared to patients without myocarditis (46.9%), and this was 
significantly different. Fourteen patients (82.3%) in the myocarditis group required ventilator 
support, where as 30 patients (46.9%) without Myocarditis required ventilation which was 
significantly different. The myocarditis group tended to stay longer in hospital, 11.7 ±4.63 (mean 
± SD) days as compared to group without myocarditis 8.59 ± 4.52 (mean ± SD) days, which was 
statistically significant. 
 
COMPARISON OF OUTCOME IN SCRUB TYPHUS WITH AND WITHOUT 
MYOCARDITIS 
Variable With myocarditis Without myocarditis P value 
Needing ICU care, n (%) 14 (82.3) 35 (54.7) 0.051 
Inotropic support (shock) n (%) 16 (94.1) 30 (46.9) 0.00 
Needing ventilation n (%) 14 (82.3) 34 (53.1) 0.05 
Needing haemodialysis n (%) 1 (5.8) 3 (4.7) 1.00 
Duration of ICU stay, mean ± SD days 3.66 ± 4.37 6.06 ± 4.37 0.0474 
Duration of hospital stay, mean ± SD days 11.7 ± 4.63 8.59 ± 4.52 0.014 
ICU mortality n (%) 1 (5.9) 6 (9.3) 1.00 
Hospital mortality n (%) 1 (5.9) 7 (10.9) 1.00 
ICU- Intensive Care Unit, with Myocarditis- (n-17), without Myocarditis- (n-64) 
Table 21 COMPARISON OF OUTCOMES IN PATIENTS WITH SCRUB TYPHUS 
WITH AND WITHOUT MYOCARDITIS 
 Figure 28 COMPARISON OF OUTCOMES IN PATIENTS WITH SCRUB TYPHUS 
 
ICU- intensive Care Unit, shock- patients requiring vasoactive, myocarditis group (n-17), no 
myocarditis group (n-64) 
 Figure 29 COMPARISON OF DURATION OF HOSPITAL AND ICU STAY IN 
PATIENTS WITH SCRUB TYPHUS WITH AND WITHOUT MYOCARDITIS 
6.11.6 Comparison of the different types of shock and use of vasoactive agents 
In this cohort of patients, the presence of shock was defined as individuals with systolic 
blood pressure less than 90 and requiring vasoactive agents. The use of vasoactive agents were 
more in the myocarditis group as compared to the group without myocarditis. Dobutamine was 
used in 8 patients (47.1%) with myocarditis and 8 patients (12.5%) in the group without 
myocarditis. The most commonly used vasoactive agent was nor epinephrine, used in 12 (70.6%) 
patients with myocarditis and in 25 (39.1%) patients without myocarditis. Eight (47.1%) patients 
in the myocarditis group received digoxin, of which 7 patients were on dobutmine as well. In 
patients without myocarditis digoxin was used in 6 (9.4%) patients. Dopamine and epinephrine 
were used in 6 (35.3%) patients in the myocarditis group and in patients without myocarditis, 
dopamine was used in 19 (29.7%) and epinephrine was used in 15 (23.4%) patients. 
COMPARISON OF THE USE OF VASOACTIVE AGENT IN SCRUB TYPHUS 
PATIENTS WITH AND WITHOUT MYOCARDITIS 
Variable  With myocarditis 
Number (%) 
Without myocarditis 
Number (%) 
P value 
Dobutamine 8 (47.1) 8 (12.5) 0.04 
Digoxin  8 (47.1) 6 (9.4) 0.01 
Dopamine  6 (35.3) 19 (29.7) 0.796 
Epinephrine 6 (35.3) 15 (23.4) 0.358 
Nor epinephrine  12 (70.6) 25 (39.1) 0.028 
Table 22 COMPARISON OF VASOACTIVE AGENTS IN SCRUB TYPHUS PAIENTS 
WITH AND WITHOUT MYOCARDITIS 
 Figure 30 COMPARISON OF VASOACTIVE AGENTS IN PATIENTS WITH SCRUB 
TYPHUS WITH AND WITHOUT MYOCARDITIS 
 
 
 
 
 
6.11.7 Types of shock 
The type of shock was classified on the basis of echocardiograhy parameters, where 
variables such as cardiac index (CI), systemic vascular resistance index (SVRI) and central 
venous pressure (CVP) were used to classify shock as cardiogenic, septic, hypovolemic or 
mixed. A total of 67 patients (including patients not requiringvasoactive agent) were assessed for 
nature of shock, in the myocarditis group 17 patients (16 patients were requiring vasoactive 
agent) and the rest 50 patients were without myocarditis. In myocarditis group 9 patients had 
features of cardiogenic shock, 4 patients had features of septic shock and 4 had features of mixed 
shock. In patients without myocarditis cardiogenic nature of shock was seen in 22 patients, 6 
patients had features of sepsis. Hypovolemic and mixed type of shock were seen in 9 and 13 
patients respectively. 
COMPARISON OF DIFFERENT TYPES OF SHOCK IN SCRUB TYPHUS PATIENTS 
WITH AND WITHOUT MYOCARDITIS 
Type of shock Myocarditis Without myoacrditis 
Cardiogenic  9 22 
Septic  4 6 
Mixed  4 13 
Hypovolemic  0 9 
Table 23 COMPARISON OF TYPES OF SHOCK IN SCRUB TYPHUS PATIENTS 
WITH AND WITHOUT MYOCARDITIS 
6.12 Systemic Vascular Resistance Index vs. Cardiac Index 
The scatter plot below shows sytemic vascular resistance index (SVRI) vs. cardiac index (CI), 
towards the right end of the plot are patients with high SVRI and a low CI, implies cardiogenic 
shock.  
 
Figure 31 – SYSTEMIC VASCULAR RESISTANCE AGAINST CARDIAC INDEX IN 
PATIENTS WITH SCRUB TYPHUS 
 
Cardiac Index normal range- 2.6–4.2 L/min/m2 , Systemic vascular resistance index  -normal 
range- 1700-2400 of dyn·s·cm
−5
 
Low CI with high SVRI- suggestive of cardiogenic shock 
High CI with low SVRI – suggestive of septic shock 
 
Towards the left and bottom of the plot are representing patients with high CI and a low SVRI 
suggesting septic shock.  
The patients ploted in the centre of the plot are the once with mixed shock.  
In scrub typhus there is a distribution of shock from the high cardiac index low SVRI septic 
shock to the low cardiac index high SVRI cardiogenic shock.  
The cardiogenic shock seems to be predominant shock, seen in nearly fifty percent of the patients 
assessed. This is summarised in the Figure 33 
 
 
 
6.13 PREDICTORS OF MYOCARDITIS 
6.13.1 Baseline characteristics 
Bivariate logistic regression analysis was done to predict factors associated with the 
development of myocarditis in scrub typhus, among the various parameters, age, sex and 
duration of illness were the baseline characters used, of which duration of illness was found 
significant. The presence of eschar and pericardial effusion were not found to be significant in 
predicting myocarditis.  
 
 
 
BIVARIATE LOGISTIC REGRESSION OF PREDICTORS OF MYOCARDITIS IN  
SCRUB TYPHUS (n- 81)- USING BASELINE CHARCTERISTICS 
Variable Odds ratio P value 95% CI 
Age  0.997 0.852 0.964 – 1.031 
Sex  1.111 0.849 0.375 – 3.288 
Fever  0.831 0.072 0.679 – 1.017 
Eschar  1.556 0.527 0.395 – 6.117 
Effusion  1.521 0.448 0.515 – 4.492 
Creatinine  0.882 0.579 0.566 – 1.375 
SOFA score 1.171 0.031 1.014 – 1.351 
APACHE II 1.044 0.253 0.969 – 1.126 
SOFA- Sequential Organ Failure Assessment, APACHE- Acute Physiology and Chronic Health 
Evaluation, ICU- Intensive Care Unit, CI- Confident Interval 
Table 24 BIVARIATE LOGISTIC REGRESSION OF PREDICTORS OF 
MYOCARDITIS IN SCRUB TYPHUS 
Among the scoring system used, SOFA and APACHE II, patients developing myocarditis tended 
to have a higher SOFA score, but not APACHE II score. Comparing creatinine values in the 
myocarditis and without myocarditis did not help in predicting myocarditis. 
6.13.2 Outcome variables 
 On performing bivariate logistic regression analysis of predictors of myocarditis using the 
outcome variables, the need for dialysis and hospital outcome was not predictive of myocarditis. 
The presence of myocarditis was associated with an increased need for mechanical ventilation 
(p<0.035) and prolonged ICU (p<0.055) and hospital stay (p<0.020). 
 
UNIVARIATE LOGISTIC REGRESSION OF PREDICTORS OF MYOCARDITIS IN  
SCRUB TYPHUS (n- 81)- USING OUTCOME VRIABLES 
Variable Odds ratio P value 95% CI 
Dialysis  1.875 0.617 0.159 – 22.01 
Ventilation  4.242 0.035 1.109 – 16.22 
ICU duration 1.212 0.055 0.998 – 1.261 
Hospital duration 1.142 0.020 1.021 – 1.278 
Hospital outcome 0.509 0.541 0.058 – 4.446 
Table 25 UNIVARIATE LOGISTIC REGRESSION OF PREDICTORS OF 
MYOCARDITIS IN SCRUB TYPHUS USING OUTCOMES 
6.13.3 Multivariate Analysis 
 A multivariate logistic regression analysis was done using factors identified on bivariate 
analysis to be associated with myocarditis. After adjusting for severity of illness and ventilator 
need, only duration of illness was associated with myocarditis.  
MULTIVARIATE ANALYSIS OF PREDICTORS OF MYOCARDITIS 
Variable 0dds ratio P value 95% C I 
Duration of illness 0.7157  0.020 0.5404 – 0.9478 
SOFA 1.1348 0.267 0.9078 – 1.418 
Duration of hospital stay 1.152 0.059 0.9947 – 1.3345 
Ventilation  1.405 0.709 0.2355 – 8.3851 
SOFA- Sequential Organ Failure Assessment, CI- confidence interval. 
Table 26 MULTIVARIATE ANALYSIS OF PREDICTORS OF MYOCARDITIS 
 
6.13.4 The Receiver Operator Curve (ROC) to look for predictors of Myocarditis 
 ROC curve was used to look for predictors of myocarditis. The variables used were SOFA score 
and APACHE II score.  
SOFA score has been shown to predict mortality in critically ill patients. We used SOFA score in 
this cohort of patients to look for prediction of myocarditis. 
 
 
Figure 32 ROC CURVE – PREDICTORS OF MORTALITY (SOFA) 
On plotting , the area under the curve was 0.546 which was not significant. 
 
6.13.5 The Receiver Operator Curve (ROC) for APACHE II score and Myocarditis 
APACHE II score is used in predicting mortality, in this cohort of patients the role of APACHE 
II in predicting myocarditis was analyzed with the help of ROC curve.  All 81 patients APACHE 
II score was calculated and included for analysis. 
 
                                              
 
Figure 33 ROC CURVE – PREDICTORS OF MYOCARDITIS (APACHE II) 
On plotting the area under the curve was 0.579, which was not significant. 
 7. DISCUSSION 
 
Scrub typhus is one of the common causes of acute febrile illness with multiorgan 
dysfunction. It is known that myocarditis can occur in association with scrub typhus infection. 
However the magnitude and impact of cardiac manifestations in scrub typhus are unknown. In 
one of the earliest pathologic studies, Levine et al (24) described 31 patients with scrub typhus 
with cardiovascular involvement. There have been case reports and small case series of 
myocarditis in scrub typhus (27,41). This prospective cohort study describes scrub typhus 
patients and their various cardiac manifestations. The sample size of 84 was calculated assuming 
a prevalence of myocarditis of 30% myocarditis. One hundred and twenty-two patients were 
screened for myocarditis of whom 19 patients had other etiology like dengue, malaria, enteric 
fever, leptospirosis and spotted fever. Eighty-one patients with confirmed scrub typhus infection 
were included in the analysis; myocardial injury was observed in 50 (61.7%) patients whereas 
myocardial dysfunction was seen in 25 (30.9%) patients. A diagnosis of myocarditis was 
presumed in 17 (21%) of patients in whom myocardial dysfunction and myocardial injury were 
evident. 
In our cohort of patients the mean age was 49.41 ± 16.07 years, the duration of illness 
prior to presentation was 8.11 ± 3.11 days and patients were predominantly from Tamil Nadu 
and its neighboring state Andhra Pradesh. These findings were similar to the previous studies on 
scrub typhus by Chrispal et al (1) and Griffith et al (2). A female predominance was seen in our 
cohort of patients, similar to other studies by Varghese et al (23) and Kim et al (10). 
 The most common presenting symptom in our study was fever (100%), followed by 
breathlessness (75.5%); the other symptoms commonly seen were  myalgia, cough, vomiting and 
altered sensorium. Varghese et at (23), in their cohort of 625 patients had reported fever in all 
patients and breathlessness in 49%. Chrispal et at (1) had shown the presenece of fever in all 
patients with breathlessness in 37.6% of the 198 patients studied in their cohort. The presence of 
fever in all patients was common in our study as compared to the rest, and more number of 
patients in our study group had presented with breathlessness. This is probably due to selection 
bias where a relatively more number of sicker patients were included in our cohort (60.5% 
patients required ICU care). 
Diabetes mellitus was the most common cormorbid illness seen in 16 (19.7%) patients 
followed by hypertension in 15 (18.5%). The presence of diabetes and hypertension in study by 
Varghese et at (23) was 11.4% and 12% respectively. A slight increase in the proportion of 
cormorbid illness in our study group could have been contributed to the small sample size. There 
was no patient in the study group with history of chronic immunosupression or features of 
autoimmune disease which can contribute to myocarditis. The number of patients with history of 
smoking and alcohol consumption was less in our cohort, this could be due to presence of female 
predominance and information bias.  
The presnece of eschar on meticulous examination was seen in 62 (77%) patients and other 
stuies had shown an eschar detection rate between 46-86% (21).  The high detection rate of 
eschar reflects the knowledge acquired by physicians.  
The common laboratory findings included thrombocytopenia (92.6%), elevated transaminases 
(92.6%), leukocytosis (51.8%) and a rise in creatinine. The transaminitis was mild, with SGOT 
being more than the SGPT suggesting a mitochondrial injury rather than a hepatic injury. In our 
study a low albumin (less than 2.5 gm %) was seen in 39 (48.1%) patients. Kim et al (42) 
reported the presence of a low albumin (less than 3.0 gm %) in 16.3% of their study group and 
hypoalbuminemia was associated with significant mortality. The pathogenic mechanism of 
hypoalbuniemia in scrub typhus is not established. However it has been postulated that due to 
vasculitis, secondary to scrub typhus, there is an increase in vascular permeability causing 
plasma protien leakage.  
The various organ involvement in the study participants was assessed using SOFA score 
and APACHE II score. The mean SOFA and APCAHE II score were 8.84 ± 3.95 and 15.68 ± 
7.01; the predicted mortality was 25.25 ± 18.59 %. In Griffith et al(2) study on critically ill 
patients the mean SOFA and APACHE II score were 10.5 and 19.6, and the predicted mortality 
was 36.3%. this suggests our cohort contianed both critically ill and not so sick patients.  
In this cohort of patients, hematological organ dysfunction predominated (96.3%),  
followed by respiratory system seen in 90.1% and cardivascular involvement in 62.9%. Hepatic 
and renal involvement were seen in 54.3% and 51.3% respectively. Central nervous system 
involvement was seen in only 18.5% of patients. These findings are similar to the previous study 
by Griffith et al (2) where respiratory sytem predominated with 96.6%, followed by 
hematological 86.2%, hepatic and renal 63.8%, cardiovascular 61.7% and central nervous system 
24.3%. The similarity in organ dysfunction between these two different cohort of patients, where 
Griffith et al(2) looks at a pure ICU cohort and our study, a mixed cohort of ICU and non ICU 
patients suggest that scrub typhus more commonly affects the respiratory, hematological and 
cardivascular system as compared to the rest. The predominant hematological organ involvement 
in our cohort could be secondary to the selection bias where all patients with acute febrile illness 
and platelets counts less than 1.5 lakhs were screened for myocarditis.  
The median organ involvement in our cohort of patients was 4, and 97.5% of patients had 2 or 
more organ involvement. This is consistent with the previous studies on scrub typhus which has 
established scrub typhus as a systemic infection involving multiple organs. 
 The cardiovascular manifestations were assessed with the help of cardiac biomarkers, 
electrocardiogram and echocardiogram. The mean (SD) CKMB and troponin T values were 6.69 
± 9.4 ng/ml and 83.1 ± 212.2 pg/ml. As troponin T is a more sensitive marker of myocyte injury 
in patients with clinically suspected myocarditis (31), it was used in screening patients for 
myocarditis. However troponin levels can be elevated in several conditions other than 
myocardial injury particularly in critically ill patients (43). Thus the myocardial injury may have 
been overestimated in our cohort. However, myocarditis was presumed only if myocardial injury 
coexisted with global myocardial dysfunction, hence the prevalence of myocarditis in our cohort 
was not affected by an overestimated myocardial injury rate. Fifty patients had troponin levels 
more than 14 pg/ml, 17 patients were diagnosed with myocarditis and the other 16 patients had 
evidence of renal failure. Seventeen patients had an elevated troponin T levels without 
myocarditis or renal failure suggesting myocardial injury in this subset of patients. 
Echocardiography was done in all patients; the mean ± SD left ventricular ejection 
fraction was 57.59 ± 14.16%. The mean cardiac output was 4.37 ± 1.38liters, and the mean 
cardiac index (CI) and systemic vascular resistance index (SVRI) were2.65 ± 0.89 and 2363.47 ± 
949.35 respectively. A low CI was seen in 33 patients and a high CI in 6 patients. A low SVRI 
was seen in 18 patients and a high SVRI in 24 patients. The different types of shock in this 
cohort of scrub typhus patients were vasoplegic, mixed, hypovolemic and cardiogenic. 
Cardiogenic type of shock was the most common type of shock; it was seen in 52.9% of patients 
with myocarditis and 34.3% in those without myocarditis. Twenty five patients had left 
ventricular systolic dysfunction. We noticed that 18 patients had mild diastolic dysfunction (E/A 
less than 1). Diastolic dysfunction presenting in scrub typhus has not been described in literature 
so far, however diastolic dysfunction has been described in other forms of myocarditis, post viral 
and lymphocytic myocarditis. In our cohort the mean E/A was 1.16 and only 2 patients had E/e‘ 
more than 15. We found that all patients with diastolic dysfunction belong to the milder form of 
the disease, James et al (44) in lymphocytic myocarditis had shown a restrictive pattern of 
diastolic dysfunction with mean E/A of 2.13 ± 1.3. 
In this cohort, 38 patients (46.9%) had sinus tachycardia which was the most common 
finding. Three patients had atrial fibrillation with no other risk factors for the same. QRS 
morphology changes were seen in 11 patients. Only 5 patients had bardyarrhythmia and 8 
patients had T inversion. One patient had supraventricular tachycardia and one patient had wide 
QRS tachycardia. None of the patients had heart block. The ECG finding in our cohort of 
patients were similar to Watt et al (45) where majority of the findings were minor and non-
specific . 
Pericardial effusion in scrub typhus has been reported as case reports (46,47); Lee et al 
(48) had described 5 cases of pericardial effusion. There are no large prospective studies in 
literature looking at the presence of pericardial effusion in scrub typhus, although a high rate of 
effusion was reported in autopsy studies. In our cohort we found pericardial effusion in 41 
patients (51%).  
Regional wall motion abnormality was seen in 12 patients, 7 patients had myocarditis. Of 
the remaining 5 patients, 2 had risk factors of diabetes and hypertension. Two patients were 
elderly 70 and 83 years old. One patient had documented mitral valve prolapse. 
Forty nine patients (60.5%) required ICU care; this suggests that our cohort contained 
more number of critically ill patients. The patients presenting in shock were 46 (56.8%) in our 
cohort where as in Varghese et at (23) it was 23.1% and Chrispal et at (1) it was 13.8%. This 
finding of a relatively high percentage of patients with shock in our cohort was probably due to a 
selection bias where more number of sick patients was included. 
In our cohort, patients with respiratory failure were managed with both invasive and non 
invasive ventilatory support, 38.50 % of the patients had acute respiratory distress syndrome 
(ARDS). 48.14% required invasive ventilation and 18.4% required non-invasive ventilation and 
7.41% required both forms of ventilation. The mean ± SD duration of ICU and hospital days was 
4.2 ± 4.4 and 9.2 ± 4.7 respectively. In Griffith et al(2) study 81% of the patients required 
ventilation. The patients requiring invasive and non invasive ventilation were 63.8% and 17.2% 
respectively. The mean duration of ICU and hospital stay in their cohort was 6.3 and 10.7 days. 
In our cohort the need for ventilation and the duration of ICU and hospital stay were less as 
compared to Griffith et al(2). 
The crude mortality in our cohort was 9.9%, which comparable to  other scrub studies, 
Varghese et al reported a case fatality rate of 9.0% (23). The mortality in Griffith et al was high ( 
24.1%)  as it included only critically ill patients (2). 
On comparing the myocarditis group with the group without myocarditis, there was no 
significant difference in the baseline characteristics, symptomatology and laboratory parameters. 
On comparing the scoring system, there was a significant difference in patients with 
cardiovascular failure between the myocarditis group and without myocarditis group (p<0.006), 
and there was no significant difference in the APACHE score between the two groups.  
On comparing secondary outcomes, there was significant difference in the need for ICU care 
(p<0.051), ventilation (p<0.05), vasoactive agent support (p<0.00), duration of ICU (p<0.047) 
and hospital (p<0.014) days. There was no significant difference in the crude mortality. 
On bivariate logistic regression analysis to predict factors associated with myocarditis, 
SOFA score and duration of illness were associated with myocarditis. Myocarditis was 
associated with increased need for ventilation and prolonged ICU and hospital stay. However on 
multivariate analysis after adjusting for severity of illness and need for ventilation, only duration 
of illness was associated with myocarditis odds ratio of 0.72 (95% CI: 0.54-0.95, p<0.020), 
suggesting that patients with myocarditis presented earlier. Chacko et al (3) had described H1N1 
patients developing myocarditis tended to present later to the hospital. Hence it can be 
hypothesized that the myocardial involvement in scrub typhus occurs early in the 
pathophysiology of the disease resulting in early presentation of these patients as compared to 
other infectious disease like influenza. The other possibility is that better knowledge of 
physicians and early recognition of complications of scrub typhus which had resulted in early 
presentation. 
 
 
8. CONCLUSION 
 
In this cohort of scrub typhus patients from south India the prevalence of myocarditis was 
21%. Myocardial injury was seen in 61.7% and myocardial dysfunction was observed in 30.9% 
participants. A mild grade of diastolic dysfunction was observed in 18% of the study 
participants. Pericardial involvement was seen in 51% in the form of mild to moderate 
pericardial effusion. ECG changes were non specific; sinus tachycardia was the predominant 
ECG finding in this cohort. The development of myocarditis increased the need for ventilation, 
prolonged the duration of ICU and hospital stay. Myocarditis was not associated with worse 
mortality in our cohort. 
 
 
 
 
 
 
 
 
 
9. SUMMARY OF CONCLUSIONS 
1. The prevalence of myocarditis in this cohort of patients was 21%. 
2. Myocardial dysfunction was seen in 30.9% of the study participants. 
3. Myocardial injury was seen in 61.7% of the study participants (over estimated by the 
presence of renal failure and critically ill patients) 
4. The prevalence of diastolic dysfunction was observed in 18% of the study participants. 
5. Pericardial involvement was seen in 51% of the study population in the form of mild to 
moderate pericardial effusion. 
6. ECG changes were non specific; sinus tachycardia was the predominant ECG finding in 
this cohort. 
7. The development of myocarditis increased the need for ventilation, prolonged the 
duration of ICU and hospital stay. 
8. Myocarditis was not associated with worse mortality in our cohort. 
 
 
  
 
10. LIMITATIONS 
 
There were a few difficulties encountered during our study. Firstly though it‘s a 
descriptive study our sample size was small. To obtain an adequate transthoracic echo view in 
certain participants were difficult. It was difficult with a poor echo window to calculate other 
parameters like cardiac index and systemic vascular resistance index. Some patients were 
excluded from study due to poor echo window and inability to get adequate echocardiography 
parameters. 
The cardiac biomarker used, troponin T though it was sensitive it lacked specificity 
resulting probably in overestimation of myocardial injury. A diagnosis of myocarditis is 
confirmed by  histological conformation of myocardial inflammation in the appropriate clinical 
setting. This requires endomyocardial biopsy or autopsy finding; however these were not 
possible in our setting. However we defined myocarditis on the basis of myocardial injury with a 
coexisting global myocardial dysfunction. 
The patients with shock were initiated on vasogenic agents and echo was performed on 
vasogenic agents. Hence the type of shock could have been altered by the use of vasogenic 
agents. 
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 ANNEXURE 1 
PATIENT INFORMATION SHEET 
TITLE: Assessment of cardiac manifestations in patients with scrub typhus in a tertiary 
care centre in South India – A prospective cohort 
What is this study about? 
This study will determine what proportion of patients with scrub typhus will develop cardiac 
complications. It also determines individuals at risk of developing such complications and 
contribution of such complications in poor outcome of these individuals. It will investigate how 
scrub typhus infection can affect the heart hence in better understanding of the disease process, 
this will help in treating such patients appropriately and will reduce the poor outcomes. 
How does this study work? 
Either the patient or the family will be requested to read the information sheet and if you decide 
to be part of the study a doctor will visit you and collect some information. Blood tests, routinely 
performed on these patients as basic care. Echocardiogram will be done to access their heart 
function .This is an non invasive method and does not harm the patient. 
What are the risks and discomforts during the study? 
All the care you receive during the study will be standard in the treatment of patients presently 
with similar problems. There is no increased harm in the study. The only difference is the 
echocardiogram a few blood investigations after forty eight hours and at the time of discharge 
whether or not you show signs or symptoms of cardiac manifestations. 
What will I get out of the study? 
The aim of the study is to improve the standard of care in such patients with cardiac 
manifestations and reduce the poor outcomes in these patients. We believe that the  information 
collected will increase the understanding of this disease and thus help minimize the 
complications related to this disease. 
What happens if I refuse? 
There will be no difference in treatment if you refuse to participate in the study. There is no 
obligation to consent to participate in the study. You will receive the same standard of care given 
to all patients in this hospital. You may choose to withdraw from the study at any time. There are 
no penalties for withdrawing from the study. 
What happens to the results? 
The results of this study will be described in a report which may be published as a paper or 
presented in a conference. At no time will any identifying characteristics of any of the 
participants be used. Your privacy will be maintained- your records will be accessed only by the 
investigators of the study and by your treating physicians. 
Any questions regarding the study may be addressed to 
Karthik G 
P G Registrar  
Christian Medical College    
 
ANNEXURE 2 
Consent Form 
 
TITLE: Assessment of cardiac manifestations in patients with scrub typhus in a tertiary care centre in 
South India – A prospective cohort 
The results obtained from the study will provide information which will help to treat your 
condition.  Also this will help in providing information so that other subjects with similar illness 
may be prevented or treated more effectively. 
You should understand that your records may undergo review and inspection by the donor 
supporting this activity. The data obtained in the study is stored in a password protected data 
base and is accessible for evaluation only with consent of the data base manager at the study 
center. Every effort will be made to protect the confidentiality of the information provided in so 
far as it is legally possible.  
You should understand that your participation in this study is completely voluntary and that you 
may withdraw at any time without prejudicing your present or future care.  You should 
understand that should your physician find it necessary and/or in your best interest, he/she may 
withdraw you from the study.  
You should understand that if you wish any further information regarding your rights as a subject for the 
study, you may contact the doctor who is treating you. You have been given opportunity to ask 
questions and have had them answered to your satisfaction. 
CONCLUSION: I have read and / or understand the consent form.  I agree to participate in this research 
study.   
                                                                                                                                                                          
Name of the Subject               Signature of Subject   Date                    Thumb print 
 
                                                                                                                                                                                         
Name of the Investigator  Signature of Investigator  Date                    Thumb 
print 
ANNEXURE 3 
TITLE: Assessment of cardiac manifestations in patients with scrub typhus in a tertiary care centre in South India – A 
prospective cohort 
 Name:                                                                   Hospital no:                               Serial no: 
Age:                   Sex: M/F       Height:               weight:                     BSA:                                  Scrub positive Y/ N                            
Admission source:  A&E /ward        In hospital transfer: Y/ N                              DOA:                                                  DOD:        
Date of ICU admission:                No:of ICU days:           No:of hospi days:                                     Day of illness(onset of fever)       
Symptomatology at presentation:                                                           Co-morbities at admission:              
Symptom Duration  Symptom  Duration   pregnancy Hypertension  Chronic smoker 
Fever   Altered sensorium  Cardiac arrest Valvular heart disease Chronic heart failure 
Cough   Breathlessness   CAD HIV infection immunosuppressant’s 
Oliguria   Seizures   CLD Diabetes Current malignancy 
Myalgia   Skin rash   CRF  others 
APACHE II:                                           SOFA:                                                   ESCHAR:  Y / N. 
TEMP: HR: pH: pO2: pCO2: Na: K: Lact: 
MAP: RR: HCO3: Creat: TC: Hct: GCS: TB: 
SOFA: 
Points 1 2 3 4 
Res PF ratio <400 <300 <200 <100 
Coagulation, Plt <150 <100 <50 <20 
Liver, bilirubin 1.2-1.9 2.0-5.9 6.0-11.9 >12 
cardiovascular MAP<70 Dopa≤5, or dobut any 
dose 
Dopa>5, or epi, norepi ≤ 
0.1 
Dopa>15, epi, norepi ≥ 
0.1 
CNS,GCS 13-14 10-12 6-9 <6 
Renal ,creat mg/dl 1.2-1.9 2.0-3.4 3.5-4.9 >5 
variable 1(<48hrs) 2(96-120) 3 
APACHE II    
CPK    
CKMB    
TROP T    
Dobutamine Y/N    
Digoxin Y/N    
Vasopressor score    
PEEP    
CVP/RAP    
Mean airway pressure    
ECG changes    
Echo findings:                                            HR:         BP:            Rhy:                            HR:         BP              Rhy:                         HR:          BP:             Rhy:           
Findings: 1(<48hrs) 2(96-120hrs) 3 
*LVEF (M-mode)    
*LVOT    
SVI    
CI    
LVSWI    
SVRI    
dP/dT    
*RWMA (Y/N)    
*E/A    
*DCT    
*E/e’    
LAP    
*RA/RV dilatation    
*IAS/IVS shifts    
*Pericardial effusion    
*valves    
Misc details.    
Vasopressor free days:                                                           duration of vasopressors: 
Ventilation :Y/ N   if Y   NIV /INV   Duration of ventilation: NIV:                  INV:                 Total:                    Duration of ICU stay(days):                                         
Duration of hospital stay(days):              ICU outcome: Dead/ Alive/ discharged at request/ PVS   Hospital outcome: Dead/ Alive/ discharged at 
request/ PVS. 
sex age EF CKMB TROPT IGM Eschar FEVER COUGH 
1 72 40 23.7 352.2 1 1 10 0 
2 57 64 3.29 17.25 1 1 7 0 
1 52 57 1.55 12.51 1 1 10 4 
2 58 84 2.35 16.86 1 1 10 0 
2 76 64 5.7 27.66 1 1 10 0 
2 72 62 1.57 63.73 1 0 7 0 
2 25 46 3.71 115.4 1 1 9 3 
1 33 48 2.37 4.03 1 0 10 0 
2 83 54 11.83 78.54 1 1 7 0 
2 71 51 6.87 10.6 1 1 10 0 
2 44 50 2.99 3 1 1 7 0 
1 41 78 3.66 5.62 1 1 14 14 
1 53 83 14.29 89.78 1 1 4 2 
2 50 71 0.756 6.07 1 1 7 0 
1 41 57   14.54 1 1 7 7 
2 51 39 6.38 146.5 1 0 5 0 
2 61 76 1.56 3 1 0 10 0 
1 46 44 4.22 10.39 1 1 4 4 
2 59 78 12.12 97.63 1 1 5 0 
1 63 65 4.57 11.57 1 1 7 0 
1 46 42 2.04 118.1 1 1 10 0 
2 23 64 1.87 8.97 1 1 7 7 
1 60 49 5.62 20.69 1 1 5 3 
2 85 51 15.69 88.6 1 1 7 7 
1 56 44 1.6 26.93 1 1 8 0 
2 50 46 1.89 13.78 1 1 14 0 
2 70 67 2.19 28.16 1 1 10 0 
2 42 73 1.09 6.32 1 1 7 0 
2 65 82 6.6 60.04 1 1 7 0 
2 50 57 1.86 16.11 1 0 7 0 
1 70 46 6.67 40.39 1 1 5 0 
1 55 53 3.24 11.29 1 0 5 2 
1 32 43 61.58 1551 1 1 4 0 
1 43 51 14.36 14.1 1 1 7 5 
1 23 69 0.56 3 1 0 7 7 
2 19 65 3.15 105 1 1 5 5 
1 52 60 2.19 9.11 1 1 14 7 
1 66 62 4.99 28.22 1 1 10 2 
1 58 65 14.38 19.31 1 1 10 0 
2 45 64 2.05 3 1 1 10 5 
1 67 57 4.15 17.51 1 1 10 0 
2 75 32 8.35 26.28 1 1 2 0 
1 38 43 0.98 4.3 1 0 3 0 
2 35 63 2.32 34.31 1 1 7 0 
1 45 60 2.09 18.38 1 0 5 1 
1 36 66 1.47 7.76 1 0 14 4 
2 20 82 2.82 4.77 1 0 3 0 
2 50 54 2.25 512.7 1 1 5 0 
2 41 63 2.72 3.52 1 0 14 0 
 
DYS AMS VOMITING HEADACH MYALGIA SEIZURES COMORB PREG DM 
0 1 1 1 0 0 0 0 0 
4 0 0 0 0 0 1 0 0 
4 0 0 1 0 0 1 0 0 
7 1 0 0 0 0 1 0 0 
3 0 0 0 0 0 1 0 0 
0 0 0 0 5 0 1 0 1 
3 0 0 0 0 0 1 1 0 
0 1 1 0 1 1 0 0 0 
1 1 0 0 0 0 0 0 0 
5 0 0 0 0 0 1 0 0 
4 0 0 2 0 0 1 0 1 
4 0 0 0 0 0 2 0 1 
2 0 0 0 0 0 0 0 0 
5 0 5 0 1 0 0 0 0 
7 0 0 0 1 0 2 0 1 
5 0 0 0 0 0 0 0 0 
0 3 0 3 0 0 1 0 0 
0 0 0 4 1 0 1 0 0 
2 0 0 0 0 0 0 0 0 
3 0 0 0 7 0 1 0 1 
3 0 1 0 3 0 0 0 0 
2 0 0 0 0 0 0 0 0 
0 1 0 5 5 0 0 0 0 
1 1 0 0 0 0 0 0 0 
5 0 0 0 0 0 1 0 0 
2 0 0 14 14 0 1 0 0 
4 0 0 10 0 0 0 0 0 
0 1 3 0 7 0 1 0 1 
2 0 0 0 0 0 0 0 0 
0 0 0 0 1 0 2 0 1 
4 0 0 0 1 0 2 0 0 
2 0 0 0 5 0 1 0 1 
3 0 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 0 
0 0 0 7 7 0 0 0 0 
5 0 0 0 0 0 1 1 0 
0 0 3 0 7 0 0 0 0 
2 0 0 0 7 0 2 0 1 
1 1 1 0 1 1 0 0 0 
5 0 0 0 0 0 0 0 0 
1 0 0 0 0 1 0 0 0 
3 0 0 0 0 0 1 0 0 
0 0 0 1 0 0 1 0 0 
2 0 0 0 5 0 0 0 0 
1 0 0 0 0 0 1 0 1 
4 0 1 0 4 0 0 0 0 
1 0 0 0 0 0 1 1 0 
1 2 0 0 0 0 2 0 1 
14 0 1 1 1 0 1 0 0 
HTN CAD SMOK ALCH HIV VHD CRF CLD DL 
0 0 0 0 0 0 0 0 0 
0 0 0 0 1 0 0 0 0 
1 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 1 0 0 0 0   0 
0 0 0 0 0 0 0 0 0 
0 0 0 1 0 0 0 0 0 
0 0 1 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 1 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 
0 0 1 1 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
1 1 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 1 
0 0 0 1 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
Resp_dis Res_fail Haem_dis Haem_fail Liv_dis Liv_fail CVS_dis CVS_fail CNS_dis 
1 0 1 0 1 0 0 1 0 
0 1 0 1 1 0 0 0 0 
1 0 1 0 0 0 0 0 0 
0 1 1 0 1 0 0 1 0 
1 0 1 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 1 0 1 0 0 0 1 0 
1 0 1 0 0 1 0 0 0 
0 1 1 0 1 0 0 1 1 
1 0 0 1 0 0 0 0 0 
1 0 1 0 0 0 0 1 0 
1 0 0 1 1 0 0 0 1 
1 0 0 1 1 0 0 1 0 
1 0 0 1 0 0 0 0 0 
2 0 0 0 0 0 1 0 0 
0 1 1 0 0 0 0 1 0 
1 0 1 0 1 0 0 0 1 
0 0 0 1 1 0 0 0 0 
0 1 0 1 1 0 0 1 0 
1 0 0 1 0 0 0 0 0 
0 1 0 1 0 1 0 1 1 
1 0 1 0 1 0 0 1 0 
0 1 1 0 0 0 0 1 0 
1 0 1 0 1 0 0 1 1 
1 0 0 1 1 0 0 1 0 
0 1 1 0 1 0 0 1 0 
0 1 0 1 0 0 0 2 0 
1 0 0 1 1 0 0 0 0 
0 1 0 1 0 0 0 1 0 
1 0 0 1 0 0 1 0 0 
1 0 0 1 1 0 0 0 0 
0 0 1 0 1 0 0 0 0 
0 1 0 1 1 0 0 1 0 
1 0 0 1 1 0 0 1 1 
1 0 1 0 0 0 0 0 0 
0 0 0 1 0 0 0 1 0 
0 0 0 1 1 0 0 0 0 
0 1 0 1 1 0 0 1 0 
0 1 0 1 1 0 0 1 0 
0 1 0 1 1 0 0 1 0 
1 0 0 1 1 0 0 1 0 
1 0 1 0 0 0 0 1 1 
0 0 0 1 0 0 0 0 0 
1 0 1 0 1 0 0 0 0 
0 0 1 0 0 1 0 0 0 
1 0 1 0 1 0 1 0 0 
1 0 1 0 0 0 0 1 0 
1 0 0 1 0 0 0 0 1 
0 0 0 1 0 1 0 0 0 
CNS_fail Ren_dis Ren_fail SOFA APACHE APACHE_pred Dialysis CREAT DOBUT 
1 0 1 15 35 83.1 1 4.5 0 
0 0 0 8 18 29.1 0 1 0 
0 1 0 5 12 14.6 0 1.32 0 
0 0 1 13 22 42.4 0 3.7 0 
0 0 0 4 12 14.6 0 1.02 0 
0 1 0 1 15 21 0 1.75 0 
0 0 0 10 13 16.5 0 0.89 0 
1 0 0 8 12 14.6 0 0.8 0 
0 1 0 12 22 42.4 0 1.48 0 
0 1 0 7 12 14.6 0 1.46 0 
0 1 0 8 19 32.2 0 2.45 0 
0 1 0 8 16 23.5 0 1.2 0 
0 0 1 14 26 56.9 0 3.6 1 
0 0 0 5 6 6.7 0 0.84 0 
0 0 0 3 10 11.3 0 1.08 0 
0 1 0 12 23 46 0 2.47 1 
0 0 0 8 17 26.2 0 0.92 0 
0 1 0 7 7 7.6 0 1.2 0 
0 0 0 12 11 12.9 0 1.08 0 
0 0 0 6 13 16.5 0 1.16 0 
0 1 0 18 30 70.3 0 2.44 1 
0 0 0 9 5 5.8 0 0.68 0 
0 0 0 10 15 21 0 1.06 0 
0 1 0 11 24 49.7 0 1.45 0 
0 1 0 10 19 32.2 0 1.8 0 
0 0 0 10 12 14.6 0 0.92 0 
0 0 0 10 14 18.6 0 1.19 0 
1 1 0 10 17 26.2 0 1.56 0 
0 0 0 11 16 23.5 0 1.04 1 
0 1 0 7 18 29.1 0 1.58 0 
0 0 0 6 11 12.9 0 1.12 0 
0 1 0 4 19 32.2 0 1.69 0 
0 1 0 13 4 5.1 0 1.21 0 
0 1 0 14 20 35.5 0 1.35 0 
0 1 0 5 8 8.7 0 1.29 0 
0 0 0 6 10 11.3 0 0.8 0 
0 1 0 5 16 23.5 0 1.2 0 
0 1 0 14 20 35.5 0 3.04 0 
1 1 0 16 31 73.3 0 2.72 0 
0 1 0 14 15 21 0 1.43 0 
0 1 0 12 15 21 0 3.04 0 
0 0 0 8 21 38.9 0 0.95   
0 1 0 4 11 12.9 0 1.54 0 
0 0 0 4 4 5.1 0 0.99 0 
0 1 0 7 14 18.6 0 3.19 0 
0 0 0 7 9 9.9 0 1.18 0 
0 0 0 7 15 21 0 0.78 0 
0 0 0 6 7 7.6 0 0.89 0 
0 0 0 6 11 12.9 0 0.45 0 
DIGOXIN dopa adr norad 
vaso 
score VENT NIV INV LVEF 
0 0 0 1   1 1 0 40 
0 0 0 0 0 1 1 0 64 
0 0 0 0 0 0 0 0 57 
0 1 0 1   1 0 1 84 
0 0 0 0 0 0 0 0 64 
0 0 0 0 0 0 0 0 62 
0 1 0 1   1 0 1 46 
0 0 0 0 0 1 0 1 48 
1 1 1 1   1 1 1 54 
0 0 0 0 0 0 0 0 51 
0 1 0 1   1 0 1 50 
0 0 0 0 0 0 0 0 50 
0 1 1 1   1 0 1 83 
0 0 0 0 0 0 0 0 71 
0 0 0 0 0 0 0 0 57 
1 0 1 1   1 0 1 39 
0 0 0 0 0 0 0 0 76 
0 0 0 0 0 0 0 0 44 
0 1 0 1   1 0 1 78 
0 0 0 0 0 0 0 0 65 
1 0 0 1   1 0 1 42 
0 0 1 1   1 1 0 64 
0 0 1 1   1 0 1 49 
1 1 1 1   1 1 1 51 
0 0 0 1   1 1 1 44 
0 1 1 1   1 0 1 46 
0   0 1   1 1 1 67 
0 0 0 0   1 0 1 51 
1 1 1 1   1 0 1 82 
0 0 0 0   0 0 0 57 
0 0 0 0   0 0 0 46 
0 0 0 0   0 0 0 53 
1 1 0 1   1 1 0 43 
0 1 1 0   1 0 1 33 
0 0 0 0   0 0 0 69 
0 1 0 1   1 1 0 65 
0 0 0 0   0 0 0 60 
0 0 0 1   1 0 1 62 
0 1 0 1   1 0 1 65 
0 0 1 1   1 0 1 64 
0 0 0 1   1 0 1 57 
  0 1 1   1 0 1 32 
0 0 0 0   0 0 0 43 
0 0 0 0 0 0 0 0 63 
0 0 0 0 0 0 0 0 60 
0 0 0 0 0 0 0 0 66 
0 1 1 1   1 0 1 82 
0 0 0 0 0 0 0 0 48 
0 0 0 0 0 0 0 0 63 
LVOT VENT NIV INV CVP VTI CO SV CI 
2.12 1 1 0 15 17.3 4.4 61.07 2.4 
1.8 1 1 0 5 20.4 5.19 51.91 3.31 
1.91 0 0 0 20 22.9 5.9 65.61 2.99 
2.36 1 0 1 5         
1.84 0 0 0 10 31.2 5.06 85.69 3.89 
1.32 0 0 0 10 26.4 2.96 36.13 1.96 
1.98 1 0 1 5 16.1 6.99 49.57 4.48 
2.17 1 0 1 15 21.8 5.16 80.62 3 
1.59 1 1 1 20 16.7 3.85 33.16 2.35 
1.97 0 0 0 15 21.1 5.92 64.31 3.68 
1.93 1 0 1 15 18 4.74 52.66 2.96 
1.95 0 0 0 15 21.1 4.79 63.01 2.58 
1.38 1 0 1 15 17.00 3.51 25.43 1.87 
1.75 0 0 0 15 22.3 5.15 53.64 2.68 
1.84 0 0 0 15 16.8 3.71 44.67 2.2 
1.72 1 0 1 20 14.4 2.48 33.46 1.31 
1.65 0 0 0 5 23.4 4.5 50.03 2.6 
1.68 0 0 0 10 21 3.72 46.55 2.16 
1.87 1 0 1 10 19.5 5.62 53.56 3.39 
2 0 0 0 5 13.2 3.7 41 2.09 
1.65 1 0 1 15 23.8 5.9 51 2.12 
1.48 1 1 0 20 22.3 4.6 38.36 3.19 
1.68 1 0 1 15 12.1 2.8 27 1.77 
1.59 1 1 1 5 27 5 54 3.05 
2.35 1 1 1 10 16.2 7.8 70 4.41 
1.53 1 0 1 20 18.9 3.4 35 2.13 
1.94 1 1 1 10 17.6 5.6 52 3.54 
1.97 1 0 1 10 16.4 4.6 50 2.86 
1.41 1 0 1 10 7.39 1.4 12 1.08 
2.06 0 0 0 15 17.3 5.1 58 3.15 
2.34 0 0 0 15 17.4 6.8 75 4.28 
1.76 0 0 0 15 15.1 3.9 37 2.23 
1.55 1 1 0 10 15.2 2.9 29 1.65 
1.61 1 0 1 10 15.1 3.6 31 2.09 
1.96 0 0 0           
2.17 1 1 0           
1.72 0 0 0 5 19.3 4.1 45 2.29 
1.74 1 0 1           
1.73 1 0 1 15 14.8 4.1 35 2.52 
1.42 1 0 1 5 21.9 3.6 35 2.52 
1.93 1 0 1 5         
1.75 1 0 1 5 16.6 5.8 40 3.79 
1.81 0 0 0 5 17.7 3.3 46 1.74 
1.62 0 0 0 15 23.6 3.9 49 2.15 
1.9 0 0 0 5 20.6 4.1 58 3.15 
2.03 0 0 0 5 16.6 5.6 54 3.37 
1.43 1 0 1           
1.72 0 0 0 15 14.4 3.45 33.46 2.17 
2.05 0 0 0 5 19.3 6.69 63.7 4.58 
SVI LVSWI MAP SVRI RWMA E/A E/e EFFUS ICU 
0.03 0.0205 72 1035.07 0 1.38 12.9 1 1 
0.03 0.03 77 1738.01 0 1.17 6.18 1 1 
0.03 0.04 87 1790.4 0 1.79 7.82 1 0 
    83   0 0.78 5.79 0 1 
0.07 0.09 87 1581.57 0 0.89 10.9 1 0 
0.02 0.03 97 3546.58 0 1.07 16.2 1 0 
0.03 0.03 74 1230.6 1 0.89 7.9 1 1 
0.05 0.07 93 2077.4   1.62 5.99 1 1 
0.02 0.03 90 2380 1 1.58 16.1 1 1 
0.04 0.05 86 1541.55 0 0.84 13.6 1 1 
0.03 0.04 84 1862.53 1 1.32 13.4 0 1 
0.03 0.03 76 1889.11 1 1.51 8.85 0 0 
0.01 0.01 85 2990.91 0 0.66 5.43 1 1 
0.03 0.04 90 2236.01 0 1.25 10.5 1 0 
0.03 0.03 80 2360.68 0 0.93 11 1 0 
0.02 0.02 79 3598.55 1 2.09 14.4 1 1 
0.03 0.04 83 2397   0.69 7.73 0 0 
0.03 0.04 93 3255.19 0 1.02 8.86 1 0 
0.03 0.03 63 1249.17 0 1.33 1.33 1 1 
0.02 0.02 73 2599.62 0 0.94 9.94 0 0 
0.02 0.03 87 2713.58 1 0.98 6.13 1 1 
0.03 0.03 73 1327.49 0 1.24 9.47 0 1 
0.02 0.03 87 3250.17 0 0.72 7.27 1 1 
0.03 0.03 76 1859.97 0 1.58 16.1 0 1 
0.04 0.06 97 1576.26 0 1.16 7.43 1 1 
0.02 0.02 77 2138.17 0 0.98 9.59 1 1 
0.03 0.04 82 1625.08 1 0.65 4.71 1 1 
0.03 0.04 86 2123.22   0.84 13.6 1 1 
0.01 0.01 75 4808.8   2.3 18.9 1 1 
0.04 0.05 93 1978.48   0.91 9.44 0 0 
0.05 0.07 93 1456.12   0.78 18.7 1 0 
0.02 0.03 103 3153   0.77 8.03 1 0 
0.02 0.03 90 3873.94   0.92 5.48 0 1 
0.02 0.03 91 3096.6   0.69 8.04 0 1 
    83     1.39 6.47 1 0 
    75     1.41 6.79 0 1 
0.03 0.04 87 2861.05   1.3 11.8 1 0 
    62     0.71 12.1 0 1 
0.02 0.02 79 2029.21   1.1 6.76 0 1 
0.02 0.02 69 2029.21   0.86 11.9 1 1 
          1.08 13.8 0 1 
0.03 0.03 79 1560.05   0.71 7.11 0 1 
0.02 0.02 73 3104.69   1.76 5.69 0 0 
0.03 0.03 80 2415.58   2.13 10.7 0 0 
0.05 0.06 87 2079.94   1.19 10.1 1 0 
0.03 0.03 70 1541.1   1.28 12.5 0 0 
    69     1.8 8.89 0 1 
0.02 0.03 97 1899.07   1.29 11.2 0 0 
0.04 0.05 90 1482.86 1 1.08 8.71 1 0 
ICU_LOS Hosp_LOS ICU_OUT HOSP_OUT DYS MCI myocard 
2 9 0 0 1 1 1 
3 8 0 0 0 1 0 
0 9 0 0 0 0 0 
9 14 0 0 0 1 0 
0 5 0 0 0 1 0 
0 9 0 0 0 1 0 
5 9 0 0 1 1 1 
5 9 0 0 1 0 0 
4 9 0 0 0 1 0 
2 7 0 0 0 0 0 
8 11 0 0 1 0 0 
0 5 0 0 0 0 0 
13 13 1 1 0 1 0 
0 5 0 0 0 0 0 
0 3 0 0 0 1 0 
6 11 0 0 1 1 1 
0 6 0 0 0 0 0 
0 6 0 0 1 0 0 
7 11 0 0 0 1 0 
0 4 0 0 0 0 0 
8 13 0 0 1 1 1 
4 8 0 0 0 0 0 
8 18 0 0 1 1 1 
4 9 0 0 0 1 0 
8 12 0 0 1 1 1 
19 24 0 0 1 0 0 
13 16 1 1 0 1 0 
5 8 0 0 0 0 0 
3 3 1 1 0 1 0 
0 8 0 0 0 1 0 
0 9 0 0 1 1 1 
0 6 0 0 0 0 0 
6 8 0 0 1 1 1 
4 5 1 1 0 0 0 
0 5 0 0 0 0 0 
3 6 0 0 0 1 0 
0 8 0 0 0 0 0 
11 19 0 0 0 1 0 
6 9 0 0 0 1 0 
9 10 0 0 0 0 0 
11 20 0 0 0 1 0 
2 2 1 1 1 1 1 
0 6 0 0 1 0 0 
0 3 0 0 0 1 0 
0 7 0 0 0 1 0 
0 4 0 0 0 0 0 
12 15 0 0 0 0 0 
0 5 0 0 0 1 0 
0 9 0 0 0 0 0 
 
